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ZHI CHEN, PhD 
University of Pittsburgh, 2007
 
Noncovalent intermolecular associations are omnipresent in chemical and biochemical systems. 
Binding constants provide a fundamental measure of the affinity of a solute to a ligand; hence 
their determination has been an important step in describing and understanding molecular 
interactions. A high-throughput method based on the concept of phase distribution has been 
developed to determine binding constants. The solute distribution coefficients between a polymer 
phase and an aqueous phase are measured in a 96-well format, in the presence and absence of the 
ligand in one of the two phases. Binding constants are then calculated through linear or nonlinear 
fitting analyses. The polymer is plasticized poly(vinyl chloride). This high-throughput approach 
has been employed in several applications. In the first one, the partition ratios (no ligand in either 
phase) of neutral solutes have been correlated with their lipophilicities (octanol-water partition 
coefficients). The established linear correlation between their logarithmic values can be used as a 
calibration curve to predict the lipophilicity of compounds with unknown lipophilicity values. 
The pKa value of a charged compound and the distribution coefficient of the ionic form can also 
be determined by this approach. In the second application, binding constants in the film phase 
have been determined for the fast evaluation of enantioselectivity of potential chiral selectors. 
The technique identified one chiral selector for the target econazole from a small library of 
twelve cyclopropyl dipeptide isosteres. Compared to other screening approaches, this protocol 
does not require the covalent attachment of either the target of the selector candidate hence 
 iv 
decreases the time and labor required for screening. In addition, the amount of the potential 
chiral selector (~100 µg) needed is significantly reduced. Similarly, intermolecular association 
can be determined in the aqueous phase. In the last application, binding constants of drug-
cyclodextrin complex formation have been measured at various cyclodextrin concentration and 
pH conditions with various cyclodextrins. Again, high throughput and low mass requirement are 
advantages of the method. 
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1.0  INTRODUCTION 
1.1 METHODS FOR THE DETERMINATION OF BINDING CONSTANTS 
1.1.1 Introduction  
Noncovalent intermolecular associations are omnipresent in chemical and biochemical systems. 
Cyclodextrin-drug inclusion, protein-drug, peptide-peptide, carbohydrate-drug, and antigen-
antibody binding are a few examples. Binding constants provide a fundamental measure of the 
affinity of a solute to a ligand; hence their determination has been an important step in describing 
and understanding molecular interactions. 
Many conventional techniques have been developed to measure binding constants. They 
can be categorized into two groups: separation based and non-separation based methods.1 The 
former category of methods physically separates the free solute and the bound solute, and 
evaluates their concentrations. Depending on how the separation is achieved, they can be further 
classified as heterogeneous or homogeneous. Chromatography,2 dialysis,3 ultrafiltration,4 surface 
plasma resonance (SPR)5 are heterogeneous methods. The free solute is separated from the 
bound one on the surface of a solid substrate. Affinity capillary electrophoresis (ACE)6-9 and 
electrospray mass spectrometry (ESI-MS)10 are homogeneous methods. The separation occurs 
either in solution or in the gas phase. Separation-free methods monitor the change in specific 
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physicochemical properties of the solute or ligand upon complexation. This category includes 
spectroscopy methods such as UV/VIS,11-13 IR,14 fluorescence13, 14 and NMR;15 electrochemical 
methods such as potentiometry,16 conductometry15 and polarography;17 as well as phase-
solubility18 and hydrolysis kinetics.19, 20 
Many of the above methods were thoroughly reviewed by Connors21 twenty years ago, 
hence this selective review will emphasize ACE and ESI-MS methods that have been emerging 
in the last two decades, and recent development in phase-distribution approaches. 
1.1.2 Affinity Capillary Electrophoresis 
Affinity capillary electrophoresis (ACE) is a term referring to the separation by capillary 
electrophoresis of substances that participate in specific or non-specific affinity interactions 
during electrophoresis.22 In the last two decades, ACE has been one of the most rapidly growing 
analytical techniques to study a variety of noncovalent interactions and in determining binding 
constants and stoichiometries. 
 A number of specialized and general ACE reviews have appeared.6, 9, 22-49 Most of them 
cover the progress and innovation in ACE during a certain period with respect to biological-
based molecular interactions. Other topics include combinatorial library screening,28 chiral 
additive evaluation,40 and cyclodextrin-drug inclusion.35, 40 Detection sensitivity improvement36 
and miniaturization48 are also continuing foci for technological innovations within ACE. The 
theoretical aspect of ACE has been reviewed by several papers,9, 23, 24, 26, 36, 37, 43, 47 including a 
discussion of the advantages and limitations of various ACE methods.24, 26, 36, 47 
 ACE may be classified into two modes: dynamic equilibrium ACE and pre-equilibrated 
ACE. The former mode requires complex forming equilibria having a lifetime of less than the 
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order of seconds. In the latter mode, the solute and ligand are pre-equilibrated prior to injection. 
For non-kinetic methods the dissociation rate must be small relative to the separation time. 
1.1.2.1 Dynamic equilibrium ACE 
Mobility-shift ACE is one of the dynamic equilibrium ACE methods in which the binding 
constant is calculated from the dependence of apparent electrophoretic mobility of the injected 
solute on the ligand concentration in the running buffer. A number of related methods exist, 
including the Hummel–Dreyer method (HD), vacancy affinity capillary electrophoresis 
(VACE),50, 51 and the vacancy peak method (VP). The details in experimental design and data 
analysis of each method will be discussed later. Except for VACE, all the other methods were 
primarily developed for high-performance liquid chromatography (HPLC) and transferred to CE. 
These methods can be subdivided according the way the binding constants are determined from 
the change of the electrophoretic mobility of the species (ACE, VACE) or from the solute (free 
and bound) concentration evaluated by the peak area (HD, VP). 
Dynamic equilibrium ACE methods assume that the equilibrium between the solute and 
the ligand is established very quickly in the capillary. Most studies also assume that the 
stoichiometry of the binding between the target and the ligand is 1:1 to establish a simple model. 
Complex formation of the solute (S) and the ligand (L) with the binding constant K1:1 is 
described by the following equation 
   S + L SL
K1:1
     (1.1) 
Hence the binding constant is 
   
][][
][
1:1 LS
SLK ⋅=      (1.2) 
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where [S], [L], and [SL] are the concentrations of the free solute, free ligand, and solute-ligand 
complex. 
1.1.2.1.1 Calculation of binding constants 
1.1.2.1.1.1 Calculation from the change in electrophoretic mobility 
In mobility-shift ACE and VACE, the apparent electrophoretic mobility of the solute, µi, 
is expressed as 
cfi SLS
SL
SLS
S μμμ
][][
][
][][
][
+++=     (1.3) 
where µf and µc are the electrophoretic mobilities of the free solute and solute-ligand complex, 
respectively. From Eq. 1.2, Eq. 1.3 can be written as 
][1
][
1:1
1:1
LK
LKcf
i +
+= μμμ      (1.4) 
Eq. 1.4 can be converted into 
][1
][)(
)(
1:1
1:1
LK
LKfc
fi +
−=− μμμμ     (1.5) 
Evaluation of experimental data is easier when Eq. 1.5 is rearranged into a linear form, for 
instance, double reciprocal plot 
)(
1
][
1
)(
1
)(
1
1:1 fcfcfi LK μμμμμμ −+⋅−=−    (1.6) 
If the solute has a much smaller concentration than the ligand, then [L] can be approximated by 
[Ltot], which is the total concentration of the ligand. Hence by plotting )(
1
fi μμ −  versus ][
1
totL
, 
the y-intercept of the linear fitting will give the value of
)(
1
fc μμ − , and K1:1 = intercept / slope. 
  Eq. 1.5 can be converted into other linear forms. For example, y-reciprocal plot 
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1:1)(
1][
)(
1
)(
][
K
LL
fcfcfi ⋅−
+⋅−=− μμμμμμ   (1.7) 
and x-reciprocal plot 
  )()(
][
)(
1:11:1 fcfi
fi KK
L
μμμμμμ −⋅+−⋅−=−   (1.8) 
All these linearization methods have different statistical weights of the data points and are shown 
in Table 1.1. However, it is difficult to know the ideal weights in practical cases.53 Moreover, 
when the binding constant is lower than ~5 M-1, bias becomes significant in the three 
linearization methods and weighting does not remove the bias.53 At high K1:1 values (K1:1 > 
~1500 M-1), the y-reciprocal method without weighting gives poorer precision than do the other 
methods, while bias is significant in the x-reciprocal plot and weighting the data does not 
alleviate the problem.53 The maximum-response range may also greatly affect the error. For 
instance, when (µi − µf) is small, an x-reciprocal plot may give the wrong values for K1:1.54 
Generally, nonlinear regression is more accurate and precise for the estimation of binding 
constants than linear regressions.53-55 A detailed discussion of statistical errors can be found in 
references.9, 26, 53-55  
1.1.2.1.1.2 Calculation from the change in peak area 
The concentrations of the free and bound solute are determined by their peak (or vacancy 
peak) area in HD and VACE methods. Eq. 1.2 can be rearranged as36, 56 
    ][][
][
][
1:11:1 totLKSLKS
SL +−=     (1.9) 
Hence, the binding constant can be determined by plotting 
][
][
S
SL versus [Ltot]. 
1.1.2.1.2 Experimental settings 
1.1.2.1.2.1 Mobility-shift ACE 
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Table 1.1. Equations used in ACE and variances in the transformed y for the different 
calculation methods. 
(Adapted from reference.54) 
Calculation methods Equations 2'yσ a
nonlinear regression 
][1
][)(
)(
1:1
1:1
LK
LKfc
fi +
−=− μμμμ  2yσ  
double reciprocal )(
1
][
1
)(
1
)(
1
1:1 fcfcfi LK μμμμμμ −+⋅−=− 4
2
)( fi
y
μμ
σ
−  
y-reciprocal 
1:1)(
1][
)(
1
)(
][
K
LL
fcfcfi ⋅−
+⋅−=− μμμμμμ 4
22
)(
][
fi
yL
μμ
σ
−
⋅
 
x-reciprocal )()(
][
)(
1:11:1 fcfi
fi KK
L
μμμμμμ −⋅+−⋅−=− 2
2
1:1 ][
1
yL
K σ⋅⎟⎟⎠
⎞⎜⎜⎝
⎛ +  
a  is the variance of the transformed y;  is the variance in (µ2'yσ 2yσ i − µf); the weight for each 
point is equal to 1/ . 2'yσ
 6 
 A capillary is filled with buffer containing L in varying concentrations and a small 
amount of S is injected. Two peaks may appear in the electropherogram, as shown in Figure 1.1a. 
The positive peak corresponds to the injected S (both free and bound). The migration time of this 
peak is monitored for the calculation of µi, the apparent electrophoretic mobility of S. 
1.1.2.1.2.2 HD method 
A capillary is filled with buffer containing S in varying concentrations and a small 
amount of L is injected. Similarly, two peaks may appear in the electropherogram, as shown in 
Figure 1.1a. The negative peak is caused by the local deficiency of S in the buffer, and the peak 
area is directly related to the concentration of S bound to L. Hence both the free and bound solute 
concentration can be determined through a series of internal or external calibrations.23 
1.1.2.1.2.3 VP and VACE 
The capillary is filled with a buffer containing both S and L. The concentration of either S 
or L is fixed and the concentration of the other component is varied. The presence of S and L in 
the capillary causes a large background detector response. After a small plug of neat buffer is 
injected, the voltage is switched on and two negative peaks (Figure 1.1b) will appear in the 
electropherogram corresponding to free S and L caused by their decrease in local concentration. 
VP uses the area of the vacancy peak corresponding to free S to construct the binding isotherm. 
A change in mobility of S or L gives the binding information for VACE. 
1.1.2.2 ACE for pre-equilibrated sample mixtures 
Similar to the HD and VP methods, methods for pre-equilibrated sample mixtures give the 
equilibrium concentrations of the solute and ligand from the electropherogram. Hence the 
binding constant can be determined according to Eq. 1.2. 
 
 7 
Time Time
A B
 
Figure 1.1. Simulated electropherograms of the methods: (A) mobility-shift ACE (HD); 
(B) VP (VACE). 
(Adapted from reference,24 with permission from Elsevier) 
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1.1.2.2.1 Frontal Analysis (FA) and Frontal Analysis Continuous Capillary Electrophoresis 
(FACCE) 
In the FA method, the capillary is filled with neat buffer and a large sample plug 
consisting of pre-equilibrated S and L is injected. Depending on the dimensions of the capillaries, 
the sample volume is typically between 20 and 200 nL, i.e., 5-20% of the total capillary 
volume.47 It is assumed that SL and L have approximately the same mobility and the mobility of 
S differs significantly. Another assumption is that the dissociation rate of the complex is slow 
enough that it can be neglected. Upon application of the electrical field, free S begins to separate 
from the mixture. Two plateaus will be detected, as shown in Figure 1.2. Plateau (a) corresponds 
to free S, and plateau (b) corresponds to S + SL. Hence the concentration of free S can be 
determined from its plateau height through an external calibration process. 
FACCE differs from the FA method by the sample introduction step. The capillary inlet 
is immersed in the sample vial during electrophoresis; hence continuous sample introduction is 
achieved.  Apparently, FACCE requires free S to migrate faster than SL. Similar to the FA 
method, the plateau height corresponding to free S can be correlated to its concentration. 
1.1.2.2.2 Kinetic CE methods 
All the previously described methods assume equilibrium between interacting molecules. 
In dynamic equilibrium mode, equilibrium must be reached rapidly. For the FA and FACCE 
methods, the equilibrium is maintained locally. These assumptions may be theoretically wrong 
since separation disturbs equilibrium.57  Considering the kinetics of the complex formation of S 
and L, Eq. 1.1 can be re-written as 
S + L SL
kon
koff      (1.10) 
 9 
AU
T
Injection 
Detection
Time 
A 
B 
 
Figure 1.2. Schematic representation of frontal analysis with capillary electrophoresis. 
Compounds: (·), solute; (○), ligand; (๏), solute-ligand complex. A: Signal height reflecting the 
free solute concentration. B: Signal height reflecting the complex concentration. 
(Adapted from reference,9 with permission from Wiley) 
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where kon and koff are rate constants of complex formation and dissociation, respectively. Hence 
according to Eq. 1.2 
         (1.11) offon kkK /1:1 =
Whitesides was the first to explore ACE for kinetic studies.58 Both the change in electrophoretic 
mobility and the shape (but not the area) of the peak were used for the determination of kon and 
koff, and thus K1:1. Recently, Krylov has developed a series of kinetic CE methods by applying 
different experimental settings and data analysis approaches. Based on various initial and 
boundary conditions – the way interacting species enter and exit the capillary, a number of 
kinetic CE methods have been designed. A thorough review of these methods has been given in 
2007.59 Here one of the approaches with simple mathematics, non-equilibrium capillary 
electrophoresis of equilibrium mixtures (NECEEM), will be described briefly.  
  In NECEEM, neat buffer is used as the background electrolyte. A short plug of the 
equilibrium mixture of S and L is injected into the inlet of the capillary, and the complex SL 
continuously dissociates during electrophoresis. If the separation of S, L, and SL is efficient, re-
association of S and L can be neglected. Hence the resulting electropherogram contains three 
peaks, as shown in Figure 1.3, representing S, L, and SL, and two exponential “smears” of S and 
L, which occur from the dissociation of SL. Figure 1.4 shows an experimental NECEEM 
electropherogram for the interaction between fluorescently labeled ssDNA and SSB protein. The 
dissociation constant and rate, Kd and koff, respectively, can be calculated as  
132
03210
1:1 /)(1
][))/(1(][
/1
AAA
LAAASKKd ++
−++==    (1.12) 
SLoff tA
AAk /ln
1
32 ⎟⎟⎠
⎞
⎜⎜⎝
⎛ +=     (1.13) 
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 S dissociated  
from SL 
L dissociated  
from SL 
tS tL tSL 
SL
S
L
Figure 1.3. Simulated NECEEM electropherogram. 
A1 is the peak area of L that either was free in the equilibrium mixture (for NECEEM), A2 is the 
peak area of intact SL at the time of its passing the detector, A3 is the peak area of L dissociated 
from SL during the separation, tL, tSL, and tS are migration times from the capillary inlet to the 
detector of L, SL, and S, respectively. 
(Adapted from reference,59 with permission from Wiley and the author) 
 
 
Figure 1.4. Experimental NECEEM electropherogram for the interaction between 
fluorescently labeled ssDNA and SSB protein. 
(Reprinted from reference,59 with permission from Wiley and the author) 
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where A1 is the peak area corresponding to L, A2 is the peak area corresponding to SL which was 
still intact at the time it passed through the detector. A3 is the area of the exponential smear left 
by L dissociated from SL during the separation. Finally, tSL is the migration time of the complex. 
[S]0 and [L]0 are total concentrations of S and L in the equilibrium mixture.  
  For NECEEM, as well as other kinetic CE methods, it is important to distinguish 
accurately the boundaries of the peaks. Two approaches have been proposed, by a control 
experiment and mathematical modeling, respectively.59 The boundary between A1 and A3 can be 
found by comparing the peaks of free L in the presence and absence of S.60 However, 
experimental errors in the range of 10% are inevitable.59 In the approach that a mathematical 
model has been developed to simulate NECEEM electropherograms, various parameters, 
including koff, vL, vSL, DL, DSL and A1 / (A2 + A3), are optimized in the regression analysis to 
minimize the deviation between the experimental and simulated traces using the least-squares 
method.61  Here vL and vSL are the electrophoretic velocities of L and SL, respectively; DL and 
DSL are the diffusion coefficients of L and SL, respectively. This modeling approach clearly 
requires effort. Nevertheless, compared to conventional ACE methods, NECEEM only needs a 
single run to determine the binding constants. Moreover, the availability of other methods based 
on various initial and boundary conditions makes kinetic CE a multi-method toolbox not only to 
measuring binding parameters but also to testing hypotheses about the interaction mechanisms.62 
Conceptually, experimental electropherograms are obtained by multiple kinetic CE methods first. 
A hypothetical model of interactions between S and L is suggested and electropherograms based 
on the hypothesis are simulated. The experimental kinetic CE electropherograms are compared 
with simulated ones to obtain the best fits. If the quality of the fit is not satisfactory, a new 
hypothesis must be developed for the interaction. The procedure is repeated until a satisfying 
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hypothesis is found. The best fits for the accepted hypothesis lead to the determination of 
stoichiometric and kinetic parameters of the interaction.62 
1.1.2.3 Comparison of ACE methods  
As a homogeneous, separation based approach, ACE does not require immobilization of the 
ligand on a solid support with the risk of altering binding properties. Other advantages of ACE 
include low sample and reagent consumption, relatively short analysis time, and availability to 
study interactions under physiologically relevant conditions with respect to pH, ionic strength, 
and temperature. There are a number of experimental approaches for the determination of 
binding constants with ACE. Each of them exhibits specific ranges of applicability, advantages 
and limitations, and can often be considered as complementary rather than competitive to each 
other.    
  Mobility-shift ACE has several specific advantages compared to other approaches: (1) 
the injected sample need not be highly purified, and (2) binding constants of several samples can 
be determined simultaneously. However, the fluctuation of the electroosmotic flow (EOF) may 
adversely influence the observed electrophoretic mobility hence a careful control or correction of 
EOF is needed. Coating of the capillary inner wall is frequently useful to control EOF and to 
avoid solute adsorption on the inner wall of the capillary that may cause peak broadening and 
inaccurate mobility measurement. Alternatively, the mobility ratio (M) can be used to estimate 
binding constants63 
   eofeofeofnetM μμμμμ /)(/ +==    (1.14) 
where µ, µnet, and µeo are the observed mobility, net mobility and electroosmotic mobility, 
respectively.  
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   MKMK
L
M Δ−Δ=Δ 1:1max1:1][     (1.15) 
where ΔM is the change in migration ratio as a function of [L], and ΔMmax is the maximum 
change in migration ratio that can be achieved with the saturation of L for complexation. This 
analysis method is independent of the capillary length, the applied voltage, and the EOF 
mobility. 
  In addition, the accuracy of mobility-shift analysis depends on the stability of the 
complex relative to the separation time. The complex dissociation halftime, expressed as ln2/koff, 
must be less than 1% of the peak appearance time.64 When the on and off rates are too slow to 
ensure establishment of a dynamic equilibrium, broadened, split, undetectable peaks may be 
observed.65 This rule holds true for other dynamic equilibrium approaches, i.e., HD, VP, and 
VACE methods. 
  For methods that use the change in peak area or plateau height for the determination of 
the free and bound solute concentrations, and thus the binding constant, special care must be 
taken to assure that the total solute concentration is known accurately, since the bound solute 
concentration is usually calculated as the difference between the total and free concentrations of 
the solute. Thus, it is assumed that no solute is lost due to capillary wall adsorption or other 
nonspecific phenomena (precipitation, etc.).66 and that the concentration in the sample 
corresponds to the concentration during electrophoresis (i.e., no stacking occurs) or at least is 
corrected based on a standard curve obtained under identical conditions.47 These requirements 
are more restrictive than the ones applied for mobility-shift ACE.  
  Contrary to dynamic equilibrium ACE methods, FA and FACCE usually require the 
complex to be quite stable so that a subsequent quantitation of the free S plateau height reflects 
the free S concentration in the sample. For molecular interactions characterized by relatively 
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rapid binding kinetics, the validity of using these two approaches should be verified. This may be 
accomplished by inspection of both the ascending and descending solute boundaries,67 which is 
possible in FA but not in FACCE. These two methods are suitable to measure K1:1 values in the 
range from 103 to 108 M-1.68 For weak interactions, the height difference between the two frontal 
zones may be too small. In this case, mobility-shift ACE may be preferred for the determination 
of binding constant. If K1:1 is too large, the plateau height for free S may be too small to be 
measured.37 
  An attractive feature of FA and FACCE is that they are insensitive to changes or 
fluctuations in migration times, EOF, and applied voltage.69 Low detection limit is also an 
advantage of these two methods. Compared to FA, FACCE requires greater sample consumption 
(e.g., 500 nL)70 but has been proposed to be advantageous since the continuous sampling may 
avoid perturbation of the binding equilibrium.71 Moreover, FACCE usually provides a broader 
plateau than FA that may be easier for quantitation.47 One of the requirements for FA and 
FACCE is that the mobilities of L and SL must be equal otherwise the free S plateau does not 
reflect the true free solute concentration at equilibrium.24, 67 This may potentially limit the 
application of FA and FACCE. The mobility requirements for other ACE methods (i.e., 
mobility-shift ACE, HD, VP, VACE) have been thoroughly discussed elsewhere.24 The 
availability of various approaches to study multiple equilibria has also been discussed there.24   
  Kinetic CE methods can determine K1:1, koff, and kon from a single electrophoresis 
experiment when 1:1 binding stoichiometry has been verified. One of the most attractive features 
of kinetic CE is that it is a multi-method tool based on various initial and boundary conditions; 
hence some proposed affinity mechanisms for a specific approach can be validated by a series of 
comparison studies. A potential problem of kinetic CE is the difficulty in distinguishing the 
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equilibrium fractions of corresponding components, which may lead to uncertainty in the 
estimate of the binding parameters.47 The applications of kinetic CE methods to higher order 
equilibria are also expected. 
  There are certainly some inherent limitations to all ACE methods for evaluating binding 
constants. For instance, it may be difficult to evaluate the association of two or more neutral 
molecules. In addition, with a few exceptions,72 applications of ACE have not been extended to 
interaction studies in non-aqueous solvents.9 
1.1.3 Electrospray Ionization Mass Spectroscopy 
Electrospray ionization mass spectrometry (ESI-MS) provides a soft ionization procedure that 
allows the transfer of weakly bound complexes from solution to the gas phase for mass analysis, 
and hence has been frequently used to study the binding behavior of a wide variety of 
noncovalent complexes.73-75 Specificity, sensitivity, and speed are several advantages of ESI-
MS.76 Moreover, ESI-MS can provide the stoichiometric information of the complex directly and 
detect multiple components simultaneously.   
  To determine the binding constant of a complex quantitatively through ESI-MS, one of 
the most frequently used approaches is the titration method. Generally, the solute concentration 
in the solution is kept constant while the ligand concentration is varied over a range of about two 
orders of magnitude.76 The gas phase ion intensities of the free and bound solute are monitored, 
and can be fit to association models for the calculation of binding constants. 
  Considering a 1:1 system  
( )][][][
][
][][
][
1:1 SLLS
SL
LS
SLK
tot −⋅
=⋅=     (1.16) 
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where [Ltot] is the total concentration of the solute. Since 
  
][][
][][][
SLS
SLSSL tot +⋅=      (1.17) 
Eq. 1.16 can be converted into 
  
1
][
][
1][][
1
][
][
1:1
+
⋅−
⋅=
SL
S
SLS
SLK
tottot
    (1.18 ) 
Define  
  IF
f
f
i
i
fi
fi
SL
S
S
SL
SL
S
SLSL
SS =⋅==
/
/
][
][     (1.19) 
where iS and iSL are the ion intensities of the free and bound solute, respectively; fS and fSL are 
the response factors of the free and bound solute, respectively. Hence Eq. 1.18 can be converted 
into 
    (1.20) 01)1][][(][)( 1:11:11:1
2 =−−−+ tottottot SKLKIFLKIF
Eq. 1.20 can be further converted into various linear forms, for instance 
1
][
][1 1:11:1 +−= IF
SKLK
IF
tot
tot      (1.21) 
By plotting 
IF
1  versus [Ltot], the slope of the linear fitt will give the value of K1:1. 
  The ratio of ion intensities (I) can be obtained from the mass spectrum for each concentration 
point. However, there is no valid method that is suitable to determine the response factor of the 
complex (fSL) and thus the ratio of response factors (F). It is often assumed that the response 
factors of the free and bound solutes are similar, and then F can be approximated to unity. 
However, different molecular species may undergo different vaporization and ionization 
efficiencies. This represents one of the biggest disadvantages of the ESI-MS method for binding 
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constant determination. In addition, ESI is not an instantaneous process, thus changes can occur 
when non-covalent complexes are transferred from the solution phase to the gas phase. For 
instance, when the kinetics of dissociation is in the same timescale of the evaporation process, 
evaporation of the droplet can cause a displacement of the complexation equilibrium towards 
association.75 The limitations of the ESI-MS method described above can be partially improved 
by competition approaches. Basically, a reference compound is mixed with the solute for 
complexation with the ligand. The reference should have a similar structure to the solute and its 
binding behavior with the ligand should be known. Therefore the binding constant between the 
solute and ligand can be indirectly obtained by comparing the two binding systems.76 From a 
practical point of view, ESI-MS should be used to determine relative binding affinities 
(selectivities) rather than absolute values. 
1.1.4 Phase-Distribution Method 
Phase-distribution methods monitor the dependence of the solute distribution coefficient between 
two phases on the ligand concentration in one phase to determine the solute-ligand binding 
constant. Usually, one of the phases is aqueous and the other is organic. The binding equilibrium 
can be studied in either phase. This method has been applied to measure binding constants for 
the complex formation of caffeine/ benzoic acid,77 solute/cyclodextrin,2, 78-85 metal ion/anion,86 
and drug/chiral selector.87 
Eq. 1.1 describes the formation of 1:1 complex. For consecutive complexation 
   S-Li-1 + L
K1:i
S-Li     (1.22) 
The binding constant (K1:i) is defined as  
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The distribution of the free solute between phase 1 and phase 2 is determined by the partition 
ratio D0
   
2
1
0 ][
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where [S]1 and [S]2 are the free solute concentrations in phase 1 and phase 2, respectively. When 
the ligand is added to phase 1, the solute distribution coefficient is 
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where n is the stoichiometry, [S-Li] (i = 1 to n) is the concentration of solute-ligand complex in 
phase 1 in various forms. Dividing Eq. 1.25 by Eq. 1.24  
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From Eq. 1.23, one obtains 
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Inserting Eq. 1.27 to Eq. 1.26 
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Plotting D/D0 versus [L], the stoichiometry and the binding constants can be obtained from 
polynomial fitting analyses.  
  The phase distribution method provides an alternative approach to measure binding 
constants of complex formation. Advantages of this method include relatively low sample 
requirement, availability to measure binding constants relevant to physiological properties (e.g., 
pH, temperature, ionic strength). However, there are several disadvantages that have to be taken 
into consideration. The mutual solubility of the two phases may interfere and complicate the 
binding equilibrium. It is even possible that some organic solvent may function as a competitor 
to bind the ligand (e.g., octanol/cyclodextrin),85 which should be carefully investigated to prevent 
from misinterpretation of the calculated binding parameters.2  In addition, all species present in 
phase 1 (e.g., free solute, free ligand, complexes) may partition to the second phase. The model 
described above assumes the partitioning of only the free solute hence has been over-simplified. 
Octanol has been the most frequently used solvent as the organic phase in phase-distribution 
studies. In this case, entrainment and emulsion can be severe problems when very hydrophobic 
compounds are studied.88 
1.2 HIGH-THROUGHPUT SOLID-PHASE EXTRACTION 
One of the most important strategies in the pharmaceutical field is to reduce time and labor 
needed for research and development of new drugs. This has led to the movement of 
pharmaceutical and biotechnology companies toward high-throughput screening (HTS) of small-
molecule compounds for their discovery programs.89 More compounds have become available 
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for further investigations. Consequently, high-throughput technologies are demanded in the post-
synthetic stages in the research and development process.  
  Since its introduction in the mid-eighties, solid phase extraction (SPE) has been a routine 
sample preparation technique used to pre-concentrate drugs present at low levels of 
concentration and to remove interfering components from complex matrices prior to quantitative 
analysis. Compared to traditional liquid extraction methods, SPE presents the following 
advantages: higher recovery, better reproducibility, faster, and easier for automation.90  The high 
throughput concept has also been embedded into SPE techniques in the last decade.91, 92 Except 
for sample preparation, high-throughput SPE technologies have been employed for synthesis 
using affinity tags,93  in-gel digestion of proteins,94 immunosorbent development,95 and chiral 
selector screening.96-98  
 Solid phase microextraction (SPME) is a special version of SPE in which the extraction 
media is a small coated fiber or tip. SPME does not have some common disadvantages of SPE 
such as clogging problems. It is especially designed for subsequent analysis by methods such as 
gas chromatography and capillary electrophoresis that have low mass detection limits.99 
Recently, a high-throughput SPME assay has been developed as a phase-distribution method to 
measure binding constant of complex formation.87,100  
1.3 OUTLINE 
The high-throughput SPE assay developed in our lab has been employed in various applications 
including the determination of intermolecular association and drug lipophilicity. Figure 1.5 
illustrates the general procedure of the assay. Briefly, plasticized poly(vinyl chloride) (PVC) 
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films are prepared in 96-well microplates. Aqueous solutions are then dispensed. The partition 
coefficient (Ppw) of a solute between the polymer phase and the aqueous phase can be correlated 
to its lipophilicity, i.e., octanol-water partition coefficient (Pow).  Chapter 2 of this dissertation 
will focus on the development of this application. When ligand compounds are dissolved either 
in the polymer films or in the aqueous solutions, the distribution coefficient (Dpw) of the solute 
that may be different from Ppw can be used to calculate the binding constant of the solute-ligand 
complex formation.  A screening method based on this concept for fast evaluation of the 
enantioselectivity of potential chiral selectors will be described in Chapter 3. The complex 
formation of the chiral selectors with the target solutes are studied in the film phase. Similarly, 
intermolecular association can be determined in the aqueous phase. Chapter 4 will introduce such 
an example by measuring binding constant of drug-cyclodextrin inclusion complex formation.  
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Add polymer/plasticizer in THF 
with/without solute 
96-well plate
Evaporate THF
Add aqueous solution  
Equilibrate (const. T) 
Measure solute conc. 
Transfer supernatant 
by plate reader or HPLC 
with/without ligand 
with/without solute 
with/without ligand 
 
Figure 1.5. General procedure of the high-throughput method to determine 
intermolecular association and lipophilicity. 
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2.0  A HIGH-THROUGHPUT METHOD FOR LIPOPHILICITY MEASUREMENT 
This work has been published in Analytical Chemistry 2007, 79, 1043-1049. Reproduced with 
permission from Analytical Chemistry. Copyright by American Chemical Society. 
2.1 ABSTRACT 
A high-throughput method has been developed for lipophilicity measurement. It measures the 
partition coefficient of a solute between a polymer phase and an aqueous phase (Ppw) in a 96-
well format. The polymer is plasticized poly(vinyl chloride) (PVC), which is widely used as a 
material for clinical containers and ion-selective electrodes. The composition is 2:1 (w/w) dioctyl 
sebacate and PVC. With six repeats, log Ppw values of 15 solutes have been determined in one 
96-well microplate in 4 h. A linear relationship between log Ppw and log Pow (octanol-water 
partition coefficient) values exists with a correlation coefficient of 0.979. The slope and intercept 
of the log Ppw vs log Pow plot are statistically indistinguishable from 1 and 0, respectively. 
Similar to the HPLC method, by using the correlation line as a calibration curve, the measured 
log Ppw values can be used to predict log Pow. This protocol is faster than the HPLC method. 
Moreover, it is straightforward to extend the protocol to the determination of the distribution 
coefficient and pKa of charged solutes. We show that the log Ppw of the neutral form of racemic 
econazole is 4.83(±0.06), for the cationic form (presumably as a dihydrogen phosphate ion pair) 
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1.68(±0.04), and the pKa is 6.15(±0.04). This method has great flexibility as well and is 
potentially fully automated. 
2.2 INTRODUCTION 
Lipophilicity represents the affinity of a molecule or a moiety for a lipophilic environment.1, 2 
Over a century ago, Overton3 and Meyer’s4 pioneering work demonstrated that the lipophilicity 
of a compound could be related quantitatively to its biological activity. As suggested by 
Collander5 and by Hansch,6, 7 the logarithmic value of the 1-octanol/water partition coefficient, 
log Pow, has been widely recognized in the pharmaceutical, biomedical, and environmental 
sciences to describe the lipophilicity of various compounds. Numerous experimental methods 
exist to measure log Pow values. The shake-flask procedure is a standard method8 to determine 
log Pow in the range of −2 to 4, but it is time and labor consuming, and requires relatively large 
amounts of pure compounds.9, 10 In addition, entrainment and octanol/water emulsions can be 
severe problems for compounds having a log Pow value larger than 4.11 The HPLC method is an 
indirect way to estimate log Pow values in the range of 0 to 6, and has also become a standard 
procedure.12, 13 A series of reference compounds is injected onto a C18 column. The compounds' 
retention factors are used to create a calibration curve with their known log Pow values. 
Compounds with unknown log Pow values are then injected, and their retention factors are used 
to predict log Pow from the calibration curve. However, this technique is only valid for neutral 
molecules since charged molecules have a far more complex retention behavior than simple 
partitioning. HPLC and other separation based methods to determine log Pow have been 
reviewed.11, 14, 15 Responding to the need for more speed and accuracy, workers have used other 
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clever approaches over the last decade. Valko16 introduced a chromatographic hydrophobicity 
index based on a fast-gradient RP-HPLC method. Tsang17 made silica-encapsulated magnetic 
nanoparticles to adsorb a tiny amount of n-octanol and measured the sample partition coefficient 
from water to the new phase. Solid-phase microextraction (SPME) has also been applied by 
several research groups to estimate log Pow.18-24 All of the above methods achieved satisfactory 
correlation with log Pow, even for very hydrophobic compounds (log Pow >6).24 There are also 
some theoretical approaches to calculate log Pow of a compound, but their reliability for new 
chemical entities and/or novel structures is not satisfactory.25 
With the development of combinatorial synthesis, high-throughput technologies have become the 
paradigm in pharmaceutical industry. Although accuracy remains a goal, small sample usage, 
ultra-fast analysis, and automation, are becoming important factors for the determination of 
physico-chemical properties in early drug discovery.11 To increase the throughput of log Pow 
measurement, an attempt has been made to transfer the traditional shake-flask method to a 96-
well format.26 However, restrictions of the shake-flask method still remained, and the yield was 
limited to one plate per day due to the detection bottleneck. An indirect method based on 
transportation experiments through octanol layers in 96-well filter plates has also been 
introduced,27 yet an unstable octanol membrane could be a problem for reproducibility. Recently, 
our group developed a high-throughput screening method for chiral selectors, which was 
modeled after the protocol for biological screening of combinatorial libraries.28 This method was 
based on target partitioning between a selector-containing polymer-film phase and an aqueous 
phase. The polymer used was plasticized poly(vinyl chloride) (PVC). Due to its wide use in 
plastic containers such as catheters and infusion bags, the partitioning of drugs, environmental 
contaminants and food components into PVC has caught the interest of many researchers.29-35 
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Plasticized PVC is also the material for ion-selective electrodes, and the lower detection limit of 
these electrodes can be dependent on the solute lipophilicity in plasticized PVC.36, 37 Plasticized 
PVC films have seen application to microextraction.38-40 Moreover, studies on PVC containers 
have shown a reasonable linear correlation between Ppw (polymer-water partition coefficient) and 
Pow.33-36, 41 Here we introduce a high-throughput method to measure Ppw in a 96-well format. A 
linear correlation between log Ppw and log Pow for 15 standard references has been established, 
which can be used as a calibration curve for indirect determination of log Pow. This application 
has also been extended to the determination of distribution coefficient and pKa of a charged 
solute. 
2.3 EXPERIMENTAL SECTION 
Chemicals and Materials. HPLC grade tetrahydrofuran (THF) and acetonitrile were purchased 
from Aldrich (Milwaukee, WI). PVC (high molecular weight, Selectophore) and dioctyl sebacate 
(DOS; Selectophore) were purchased from Fluka (Ronkonkoma, NY). Water used in all the 
experiments was purified with a Milli-Q Synthesis A10 system (Millipore, Bedford, MA). All 
the solutes were purchased from commercial sources with purities greater than 99%. Costar 
polypropylene 96-well microplates (flat bottom, 330-µL well volume), BD Falcon UV-
transparent 96-well microplates (370-µL well volume), and thermal adhesive sealing films were 
purchased from Fisher Scientific Co. (Pittsburgh, PA). 
Equipment. A Deep Well Maximizer (or BioShaker) (model M·BR-022 UP, made by Taitec and 
distributed by Bionexus Inc., Oakland, CA) was used to speed up the solute distribution kinetics 
and control the temperature for better reproducibility. UV spectra were acquired with a 
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SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA) in UV-transparent 
microplates. An X-LC (Jasco Inc.) HPLC system was used to measure the retention factors of 15 
standard compounds on a C18 column (Prevail C18, 4.6 × 100 mm, particle size 3 µM, Alltech 
Associates, Inc., Deerfield, IL). For high-throughput determination of econazole concentration, 
the same HPLC system with a UPLC C18 column (1.0 × 50 mm, particle size 1.7 µM, Waters, 
Milford, MA) was used.  
General Procedure for Ppw Determination. Figure 2.1 gives the sequence of operations for the 
Ppw determination. The plasticized PVC films were prepared in polypropylene 96-well 
microplates. Aliquots of the solute solution were then dispensed. The plates were covered by 
adhesive sealing films and incubated in a shaker (500 rpm, 25 °C). In order to determine the 
equilibration time, a kinetic study was performed. The concentration of solute remaining in the 
aqueous phase was measured as a function of time. All other data generated were at equilibrium. 
To determine the solute concentration, the supernatant from each well was transferred to a UV-
transparent microplate. A microplate reader was used for UV absorbance measurement. The 
partition coefficient, Ppw, was then calculated as 
Φ⋅
−=
1
10
C
CCPpw      (2.1) 
Here C0 is the initial solute concentration in the aqueous phase, C1 is the concentration at 
equilibrium, and Φ is the phase ratio. 
Preparation of Plasticized PVC films. PVC (1.67 g) and DOS (3.33 g) were dissolved in 200 
mL THF in a volumetric flask. A multi-channel pipette was used to dispense the solution to the 
wells of a polypropylene 96-well microplate. The plate was placed in the hood for 6 hours for 
evaporation of the THF, and the films were formed at the bottom of each well. The volume of 
each film was estimated as 
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Add PVC/plasticizer in THF 
96-well plate
Evaporate THF
Add target, equilibrate 
(const. T) 
transparent plate, measure 
Transfer target to a UV- 
absorbance of target 
 
Figure 2.1. General procedure for Ppw determination. 
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200/5 ×≈×=   (2.2) 
Here Vsolution is the volume of the THF solution used in each well and dfilm is the density of the 
film, which is estimated as 1 g/mL. In this paper, 100 µL of the THF solution was dispensed in 
each well, so the volume of each film was ~2.5 µL.  
Protocol to determine the Ppw values of the 15 reference solutes. Fifteen compounds were 
dissolved in water at the concentration of 0.5 mM. The solutions were then filtered. As shown in 
Table 2.1, aliquots of the solutions were dispensed to the polypropylene microplate in which the 
plasticized PVC films were made. The volume of the dispensed aqueous solution in each well 
was 200 µL, and six repeats were performed. The plate was then sealed by an adhesive film and 
equilibrated in the shaker (500 rpm, 25 °C) for 4 h. At the same time, aliquots of 100 µL of each 
standard solution were dispensed to a UV-transparent microplate. Again, six repeats were 
performed. The UV absorbance of each standard was measured at its maximum absorbance 
wavelength by the microplate reader. Note that, for all the measurements, the same amount of 
water in the wells was used as reference for background deduction. For standard i, Ai0 (i = 1-15) 
is defined as its average absorbance. The UV absorbance of the standards at partition equilibrium 
was measured similarly: After 4 h, from each well of the polypropylene plate, 100 µL of the 
supernatant was transferred to a UV-transparent plate. The corresponding UV absorbance data 
were again collected by the microplate reader. Ai is defined as the average absorbance for 
standard i at equilibrium. As shown in Table 2.1, there was no solute in wells H7-12. The UV 
absorbance in those wells (Ab) was due to the small aqueous solubility of DOS. Thus, the 
partition coefficient for standard i could be calculated as 
Φ⋅−
−−=
)(
)(0
bi
bii
pw AA
AAAP       (2.3 ) 
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Table 2.1. Layout of the 15 reference solutes in the 96-well microplate 
1-6 7-12 
A 4-acetylpyridine acetophenone 
B aniline methyl benzoate 
C acetanilide 4-chlorophenol 
D benzyl alcohol ethyl benzoate 
E 4-methoxyphenol 2,3-dichloroaniline 
F phenol ethylbenzene 
G benzonitrile benzophenone 
H phenylacetonitrile water 
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Here, Ф = 2.5 µL / 200 µL = 1 / 80. 
The protocols to measure the Ppw values of other solutes are similar. 
HPLC method to determine the k values of the 15 reference solutes. The retention factors of 
the 15 standard references were measured on the Alltech C18 column. The mobile phase was 
water/acetonitrile (50/50), with a flow rate of 0.6 mL/min. The back pressure was ~2550 psi. 
Two repeats were performed for each solute. 
Protocol to determine the Dpw values of econazole at different pH. To measure distribution 
coefficient, Dpw, the protocol had some minor modifications. The solute was initially prepared in 
the polymer film. The solute econazole was dissolved in THF at 200 µM. Each well received 200 
µL of the solution. The PVC/DOS solution was then dispensed, and the same procedures as 
previously described were followed to make the films. For distribution experiments, 10 mM 
phosphate buffer solutions with various pH values were added to the films. The econazole 
concentration in the supernatant at equilibrium (C) was determined both by HPLC and by UV 
absorbance as above. The distribution coefficient at a specific pH could be calculated as 
Φ⋅
−= pH
pHpH
pH
pw C
CCD 0     (2.4 ) 
Here, C0 = 200 µM. 
The HPLC method to determine econazole concentration. To minimize the ionized form, 
econazole samples in acidic buffer (pH <4) were diluted 20 times by 25% ACN + 37.5 mM 
Na2HPO4 solution; samples in near-neutral buffer (6 < pH < 8) were diluted twice by 50 mM 
Na2HPO4 solution. The column used was the Waters UPLC C18 column. The mobile phase was 
50 mM Na2HPO4/acetonitrile (65/35), with a flow rate of 0.2 mL/min. The back pressure was 
~6400 psi. To ensure reproducibility, the full-load injection mode was used (injection volume 30 
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µL; loop volume 1 µL). The peak area of econazole was used for the calibration and 
determination of its concentration. The time per analysis is ~60 s. 
2.4 RESULTS AND DISCUSSION 
When a solute partitions from the aqueous phase to the film phase, its UV absorbance in the 
aqueous phase should continually decrease until equilibrium. As shown in Figure 2.2, 4 h is 
needed for the partitioning of solutes to reach equilibrium. Careful inspection of the curves 
shows that the equilibration time is longer for more hydrophobic compounds. In this paper, all 
the solutes (except econazole) have log Pow values in the range of 0-3.2, so all the partitioning 
experiments were performed for 4 h, if not stated otherwise. 
  The Organization for Economic Co-operation and Development has recommended the 
15 compounds listed in Table 2.2 as the reference substances for the HPLC method.13 As shown 
in Figure 2.3, they span a wide range in hydrogen bond basicity and acidity. Figure 2.4 shows the 
correlation between the log Pow values and the log Ppw values for these 15 compounds. The least-
squares regression equation of log Ppw versus log Pow (Table 2.2) leads to   
   )108.0(185.0log)054.0(933.0log ±+±= owpw PP   0001.0170.0979.015 <
psern
          (2.5) 
where n is the number of compounds studied, r is the correlation coefficient, and se is the 
standard error of the regression. This regression line can be used as the calibration curve for 
indirect determination of log Pow as in the HPLC method. Briefly, for compounds that have 
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 Figure 2.2. Kinetic UV absorbance of solutes in the aqueous phase during the partition 
equilibration process. 
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Table 2.2. The 15 reference solutes and their values of log Pow, log Ppw, and log k 
Number Standards log Pow log Ppw log k 
1 4-acetylpyridine 0.5 0.70 ± 0.07 0.234 ± 0.015 
2 aniline 0.9 1.28 ± 0.20 −0.130 ± 0.002 
3 acetanilide 1.0 1.06 ± 0.11 −0.046 ± 0.002 
4 benzyl alcohol 1.1 0.95 ± 0.32 −0.052 ± 0.002 
5 4-methoxyphenol 1.3 1.42 ± 0.06 −0.082 ± 0.002 
6 phenol 1.5 1.48 ± 0.09 −0.002 ± 0.002 
7 phenylacetonitrile 1.6 1.50 ± 0.06 0.288 ± 0.001 
8 benzonitrile 1.6 1.66 ± 0.06 0.278 ± 0.001 
9 acetophenone 1.7 1.84 ± 0.11 0.278 ± 0.001 
10 methyl benzoate 2.1 2.45 ± 0.04 0.464 ± 0.001 
11 4-chlorophenol 2.4 2.16 ± 0.05 0.264 ± 0.002 
12 ethyl benzoate 2.6 2.67 ± 0.05 0.658 ± 0.002 
13 2,3-dichloroaniline 2.8 2.81 ± 0.10 0.620 ± 0.001 
14 ethylbenzene 3.2 3.19 ± 0.28 0.913 ± 0.005 
15 benzophenone 3.2 3.17 ± 0.19 0.786 ± 0.006 
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 Figure 2.3. Linear correlation of log Ppw - log Pow for the 15 reference solutes. 
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 Figure 2.4. Hydrogen bond acidity (α2H) and basicity (β2H) map of the 15 reference solutes. 
( )42,49,50 (*) Estimated (2-chloroaniline, α2H = 0.25, β2H = 0.31; 3-chloroaniline, α2H = 0.30, β2H 
= 0.30. 2,3-Dichloroaniline should be slightly more acidic but less basic than both of them) 
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unknown log Pow values, measure their log Ppw values and use the regression line to predict their 
log Pow values.  
Figure 2.5 gives the correlation between the log k (RPLC) and log Pow values of the same 
15 reference solutes. The least-squares regression equation is 
)08.0(49.0log)04.0(41.0log ±−±= owPk   0001.0110.0952.014
..
<
pesrn
          (2.6) 
Note that the data point of 4-acetylpyridine is not used for regression analysis since it is an 
obvious outlier. The linear correlation coefficient would decrease to 0.879 if that point had been 
included. The r values of the two correlations (after discarding the outlier) are similar, indicating 
that the precision of our method is similar to the HPLC method for indirect determination of log 
Pow. However, as the slope of the HPLC method is lower, the precision in the slope of the 
polymer-based method is better than that of the HPLC method based on comparing the relative 
standard deviation of the two slopes. Besides lipophilicity, H-bonding also plays an important 
role in determining the Pow value of a solute. As a result, due to the diversity of the H-bonding 
ability of PVC/DOS (1:2) (β = 0.53, α = 0),40 n-octanol (β = 0.45, α = 0.33)42 and C18 (β = 0, α = 
0), the linear correlations are not perfect among systems when the solutes have various numbers 
of H-bond donors and acceptors. Note that Pow is just a term to picture lipophilicity. Actually, to 
describe lipophilicity, the ideal partition system should use an organic phase that is free of polar 
binding forces, and a hydrocarbon solvent such as cyclohexane or hexadecane43 should serve as a 
better reference than octanol. However, some practical issues hindered their popularity. 
Furthermore, one of the most important reasons making Pow a standard term to describe 
lipophilicity is the large number of data measured.  
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 Figure 2.5. Linear correlation of log k - log Pow for the 15 reference solutes. 
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 Studies in drug partitioning behavior in polymers have shown that the slope of the log 
Ppw - log Pow correlation line has an inverse linear relationship to the polarity or the solubility 
parameter of the polymer,44, 45 which can be used to predict drug solubility in polymers. It also 
reflects how sensitive the solvent system is to changes in lipophilicity of solutes.7 In Eq. 2.5, the 
slope is close to 1 (t = 1.24, p = 0.24), indicating that the polymer material (PVC:DOS = 1:2) (π* 
= 0.64)40 has a similar polarity to octanol (π* = 0.40).42 The intercept of the log Ppw - log Pow 
correlation line can be used as a measure of the polymer lipophilicity.7 The intercept of Eq. 2.5 is 
close to 0 (t = 1.71, p = 0.11), indicating that DOS plasticized PVC (PVC:DOS = 1:2) has a 
similar lipophilicity to octanol. The intercept is also linearly related to the solubility of water in 
the polymer phase.7, 44, 45 
In another application, log Ppw values of the three positional isomers of nitroanisole were 
measured and correlated to their experimental log Pow values. The linear regression equation is:  
  )082.0(210.0log)041.0(054.1log ±+±= owpw PP   025.0013.09992.03
.. pesrn
          (2.7) 
For isomers that have the same functional groups, the partition behavior is more similar than for 
a set of compounds that have different functional groups. The measured log Ppw values, as well 
as the experimental log Pow values from the literature, and the estimated log Pow values from 
online-software calculations, are listed in Table 2.3. Obviously, the order of the three 
experimental log Pow values of the isomers matched the order of the three log Ppw values very 
well: 3-nitroanisole > 4-nitroanisole > 2-nitroanisole. For the calculated log Pow values, the 
orders did not match. This mismatch of the calculated data with the experimental data confirms 
our statement in the introduction, that theoretical calculations of log Pow sometimes are not very 
accurate.  
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Table 2.3. Log Pow and log Ppw values of the 3 isomers of nitroanisole 
log Pow
Targets log Ppw
Exp. esc.syrres.com logP.com 
2-nitroanisole 2.03 ± 0.03 1.73 1.89 1.90 
3-nitroanisole 2.49 ± 0.06 2.17 1.89 1.97 
4-nitroanisole 2.36 ± 0.07 2.03 1.89 2.02 
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 For a homologous series of solutes, the free energy for the partitioning process linearly 
increases with increasing number of methylene groups in a straight chain. Figure 2.6 confirms 
this relationship by examing the log Ppw and log Pow values of four alkyl 4-hydroxybenzoates. 
Since methyl 4-hydroxybenzoate has no methylene group, only three points from each data set 
were used for the regression analysis. The least-squares regression equations are 
)025.0(373.1)012.0(480.0log ±+±= mPpw    015.0016.09997.03
. pesrn
          (2.8) 
   )025.0(927.1)012.0(550.0log ±+±= mPow    013.0016.09998.03
.. pesrn
          (2.9) 
The two slopes are not significantly different (t = 4.12, p = 0.15). The free energies required for a 
methylene group to transfer from the organic phases to the aqueous phase are 2.74(±0.06) kJ/mol 
from the polymer phase to water and 3.13(±0.06) kJ/mol from octanol to water.  
Compared to the HPLC method, which requires ~5-20 min for determining the retention 
factor of 1 sample, the new technique is more suitable for a large number of solutes, for instance, 
combinatorial libraries. The time needed to prepare one plate of PVC films is ~6 h. Increasing 
the number of plates will not significantly change the processing time since the bottleneck of the 
film-making procedure is THF evaporation. The equilibration time is 4 h, regardless of the 
number of plates. Dispensing solutes to one plate takes ~15 min, and UV absorbance reading 
adds another 15 min. As described above, the time scale for both methods is about the same if 
the log P values of only 30 samples are to be determined. However, if the analysis of more 
compounds is required, this technique will save time. Moreover, it has the potential to build a 
larger database for Ppw than for Pow.   
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 Figure 2.6. Linear correlation of the log Ppw and log Pow values versus the number of 
methylene groups in alkyl 4-hydroxybenzoates. 
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The method assumes that partitioning only occurs between the two phases: aqueous and 
polymer. Loss of solute to the microplates due to sorption can lead to misinterpretation. 
Polypropylene is a good packaging material for drug-like compounds because the sorption effect 
is small or nonexistent.46-48 We tested the concentration stability of the solutes in the 
polypropylene plate and didn’t see any apparent loss. Therefore, we have assumed that solute 
loss to the plate during the equilibration process is negligible. Solute adsorption on the surface of 
the plasticized PVC film should also be considered. Calculations show that if a monolayer of 
well-packed solute (M.W. ~ 200) had been adsorbed on the film surface, only about 0.3% of the 
solute would be lost from the aqueous solution at 0.5 mM. If a lower solute concentration is 
used, this could become more of a problem. When using the UV-transparent plate, buffering 
sometimes may be needed since mass loss of basic compounds to polystyrene materials could be 
severe.46 Attentions should also be paid to volatile solutes: instant covering and quick action to 
measure UV absorbance in the plate are needed. 
Figure 2.7 shows the estimated measurement error associated with the calculated log Ppw 
value, based on the following assumptions: (1) Concentrations are measured by optical 
absorbance in the aqueous phase; (2) Ai0 = 1, sAi0/Ai0 = 0.015; (3) Ab = 0.06, sAb = 0.006; (4) sAi/Ai 
= 0.037 (sAi ≥ 0.003); (5) four repeats are performed for each measurement. sAi0, sAb, and sAi are 
the standard deviations of Ai0, Ab, and Ai, respectively. The selected values of sAi0/Ai0, Ab, sAb, and 
sAi/Ai are the averages obtained from experiments. Ppw values are calculated from Eq. 2.3 with 
various Ai values. The standard deviation, s, is primarily a result of pipetting errors during the 
processes of film preparation, solute dispensing, and supernatant transferring, but not from the 
determination of UV absorbance. With a more precise liquid-handling technique, it is possible to 
reduce the pipetting errors, as well as the propagated error of log Ppw. At one fixed phase ratio, it 
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 Figure 2.7. Estimated error of log Ppw at various phase ratios (Ф). 
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is possible to obtain precise measurement results (slogPpw < 0.2. slogPpw is the standard deviation of 
log Ppw) for ~2.6 log Ppw units. Changing the phase ratio will greatly extend the applicable range, 
e.g., by doubling or halving the phase ratio, the boundaries will be 0.3 unit larger or smaller, 
respectively. This strategy is similar to changing the strength of the mobile phase or the length of 
column to adjust the retention time when using the HPLC method. 
Increasing the number of independent determination, which is very easy when using a 
microtiter plate, will also help to decrease measurement error. Therefore, depending on the 
acceptable precision, an operator performing the protocol can flexibly choose the necessary 
phase ratio and determination repeats. 
This high-throughput technique can also be applied to determine the distribution 
coefficient (Dpw) of a substance at various pH values. Some minor modifications of the protocol, 
as shown in the experimental section, made the measurement even more convenient and 
extended the range of log Dpw accessible at a single phase ratio. Figure 2.8 shows an example of 
the application. Econazole (Figure 2.9) is a basic compound that has two ionizable groups, with 
only one of them ionizable at pH ≥ 1 (pKa = 6.69, log Pow = 5.32, calculated using Advanced 
Chemistry Development (ACD/Labs) Software V8.14 for Solaris). Thus its log Dpw value 
increases with increasing pH of the buffer, and can be further elucidated by the log D estimation 
formula for bases: 
aa pKpHpHpK
PPpHD −− +++= 101
'
101
)(    (2.10) 
where P is the partition coefficient of the neutral form while P' is that of the ionized form. The 
equilibration time was 6 h. Two parallel experiments were performed, using the plate reader and 
HPLC to determine the econazole concentration at equilibrium, and two sets of log Dpw values 
were correspondingly acquired. Applying nonlinear least-squares curve fitting, as shown in 
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 Figure 2.8. Log Dpw of econazole at various values of pH. 
 
Figure 2.9. Econazole structure 
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Figure 2.8, the log Ppw, log P'pw, and pKa values of econazole can all be obtained, which are 
3.53(±0.03), 1.69(±0.04), and 5.41(±0.06), respectively, when the plate reader was used, and 
4.83(±0.06), 1.68(±0.04), and 6.15(±0.04), respectively, when the HPLC was used. Apparently 
the latter set of data are more accurate. The two fitting curves almost overlap at low pH, but have 
a clear variance when pH >7, where log Dpw values are larger than 3.5. This is in good agreement 
with our previous calculation about the applicable range of log Ppw when using the plate readeras 
the detection tool. The plate reader can only quantitate the econazole concentration above 10 
µM, which limits the measurable range of log Dpw to 3.5, while HPLC on-column 
preconcentration helped to quantitate econazole concentration as low as 0.03 µM, with the 
extension of the measurable range of log Ppw and log Dpw to 5.7. The estimated error associated 
with log Ppw (or log Dpw) is again shown in Figure 6, based on the following assumptions: (1) 
Solute concentrations in the aqueous phase are measured by HPLC with on-column 
preconcentration; (2) C0 = 1, sC0/C0 = 0.015; (3) sC/C = 0.037 (when C > 0.0001); (4) four 
repeats are performed for each measurement. C0 is the initial relative concentration of the solute 
and C is the relative solute concentration at equilibrium. sC0 and sC are the standard deviations of 
C0 and C, respectively. Ppw values are calculated from Eq. 2.1. For more straightforward 
comparison, the selected values of sC0/C0 and sC/C are the same as sAi0/Ai0 and sAi/Ai, as in the 
previous estimation of log Ppw error when using the plate reader to measure solute concentration. 
Apparently, with HPLC as the detection tool, the errors at high log Ppw are much smaller. For 
quantitative analysis of the solutes, one HPLC run needs ~30-60 s. Although slower than the 
plate reader, it is still reasonably rapid. Again, depending on the desired application, an operator 
performing the protocol can flexibly choose the most suitable detection technique. Since the 
traditional HPLC method for lipophilicity measurement is usually inaccurate for charged 
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compounds, the applicability of the system for the determination of log D and pKa values is 
another advantage over it. 
2.5 CONCLUSIONS 
A new method for lipophilicity measurement using high-throughput technologies was 
successfully developed. In this method, the partition coefficient of a substance between a 
polymer phase and an aqueous phase (Ppw) in is measured 96-well microplates. With 6 repeats, 
The log Ppw values of 15 compounds can be determined simultaneously with six replicates per 
data point. A linear relationship between log Ppw and log Pow has been established. By using the 
correlation line as a calibration curve, the measured log Ppw values can be used to predict log 
Pow. This method proven to be more accurate than some software for the estimation of log Pow. It 
can also help to understand the partition mechanism among different solvent systems. Compared 
to the HPLC method, our protocol is more time-saving for combinatorial libraries, and it is not 
only applicable for the partition coefficient determination of neutral compounds but can also be 
utilized as a tool for distribution coefficient and pKa measurement. This method has great 
flexibility as well, as instruments exist to make it fully automated. 
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3.0  A SCREENING METHOD FOR CHIRAL SELECTORS THAT DOES NOT 
REQUIRE COVALENT ATTACHMENT 
Part of this work has been published in Journal of the American Chemical Society 2006, 128(7), 
2208-2209. Reproduced with permission from Journal of the American Chemical Society. 
Copyright by American Chemical Society. 
3.1 ABSTRACT 
A high throughput screening protocol for chiral selector discovery was developed based on target 
distribution between an aqueous phase and an organic phase. Screening for intermolecular 
association was carried out by partitioning experiments in the presence and absence of a chiral 
selector in the organic phase. A novel partition ratio measurement system was developed using 
96-well microplates. This protocol was validated and applied to a small library. Among 12 
cyclopropyl dipeptide isosteres that were screened, eight bound econazole, and one had 
measurable chiral selectivity. The advantages of the method are that it does not require the 
covalent attachment of either the analyte or the selector, and the required amount of the potential 
chiral selector (~ 0.1 mg) is significantly reduced. 
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3.2 INTRODUCTION 
The enantiomers of a chiral drug often differ significantly in their pharmacological,1 
pharmacodynamic and pharmacokinetic effects.2 For safety, efficacy and efficiency, the demand 
for enantiopure drugs over the racemic form has been increasing rapidly.3 The process cost for a 
reaction/separation sequence is much lower than for an enantioselective synthesis,4 thus chiral 
separation of racemic compounds has been a focus of interest in the pharmaceutical industry. At 
the analytical to semi-preparative scale, particularly in drug discovery, liquid chromatography 
(LC) on chiral stationary phases (CSPs) has been the most widely utilized technique for chiral 
separations.5 Numerous CSPs have been developed by research groups worldwide, and some 
commercial sources have introduced various broadly applied CSPs.5 However, there are still 
many racemic compounds that can not be separated or separated well by currently available 
columns. The desire for more generality, better selectivity, more robustness and predictability 
drives the search for new CSPs.6  
  Amino acids and their derivatives, as well as peptides, due to their many structural 
forms and their ease of modification and immobilization, are natural sources for CSPs.7 Pirkle 
pioneered using amino acid derivatives in the development of CSPs based on charge-transfer 
interactions.8 CSPs based on synthetic peptides have also been widely used in LC. Work in this 
field has been reviewed.9, 10 New CSPs based on peptidomimetics have also been introduced.11 
Recently, parallel synthesis and combinatorial studies of peptides as well as peptidomimetics 
libraries have been developed rapidly.12-15 These peptidomimetics not only have demonstrated 
some clinical utility,16 but also they provide a diverse chiral pool from which chiral selectors 
may be obtained. For development and application of new chiral selectors, it is essential to have 
knowledge of the chiral recognition mechanism. Though many models have been established and 
 64 
predictions have been made towards the chiral recognition mechanism, for instance, three-point 
interactions17 for Pirkle-type CSPs, host-guest chemistry18 for cyclodextrin-based CSPs, there is 
yet no thorough understanding at the molecular level in this very complicated subject.19 Today 
most CSP designs are still based on previous experience or some semi-empirical theories.  In 
order to find good chiral selectors from a large library, the safest way is to have a universal 
screening method. 
  The reciprocal principle (if a CSP derived from (+)-A can distinguish between (+)-B 
and (−)-B, then a CSP derived from (+)-B may distinguish (+)-A from (−)-A) was introduced by 
Pirkle for the screening of new CSPs.20, 21 The target was attached to a stationary phase and the 
candidate selectors were resolved on the column. This principle avoids immobilizing every 
selector to a stationary phase. It has been applied successfully by subsequent researchers. 
However, the range of targets could be used successfully for screening was limited due to “tether 
effects”.22 Welch et al.22 used LC/MS to check the enantioenrichment of the target after 
adsorption by a CSP. Isotopically labeled enantiomers were required for the screen to Welch.  Li 
et al. were also very active in the development of a new screening method for chiral selectors.23-
26  Similar to the Welch’s group, the target was allowed to adsorb on the CSP and 
enantioenrichment in the supernatant was analyzed by multiple detection methods. We note that 
all the current screening methods require the immobilization of either the target or the selector to 
a stationary phase; some of them also require packing and using the CSP in a column. These 
steps require time, labor and material. It would be extremely useful to have a library screening 
protocol for chiral selector discovery that would function within the standard regimen for 
biological screening of combinatorial libraries. That means using sub-mg quantities of candidate 
selectors in DMSO solution in 96- or 384-well microtiter plates.   
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Here, such a method based on target distribution between an aqueous phase and an 
organic (film) phase in a microtiter plate is introduced.27-29 Partitioning experiments are 
performed in the presence and the absence of a candidate selector in the organic phase. The 
difference in the observed distribution of the target reports on the binding of the target to the 
selector. Since ordinary organic solvents are difficult to work with, especially at low volume, 
thin polymer films are preferred as the organic phase. Plasticized polyvinyl (PVC) films have 
been used to study molecular recognition,30-32 so it is naturally a good choice for chiral 
recognition. Figure 3.1 gives the sequence of operations for the screening procedure. In this 
design, the aqueous phase contains target initially. Alternatively, target and selector may be 
combined in the film phase initially. The applicability of this method is validated using a known 
chiral selector and target analyte, N-(3,5-dinitrobenzoyl)-phenylglycine (DNBPG; Figure 3.2, 1) 
and 2,2,2-trifluoro-1-(9-anthryl)ethanol (TFAE; Figure 3.2, 2). TFAE is defined as the selector, 
and observe the release of DNBPG from the PVC/DOS film to the aqueous buffer solution, with 
or without the selector in the film. This method was then used to screen a small library of 
potential chiral selectors for econazole (Figure 3.2, 3), an antifungal agent.  
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Add target, equilibrate 
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Figure 3.1. Screening protocol. 
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Figure 3.2. N-(3,5-dinitrobenzoyl)phenylglycine (DNBPG; 1), 2,2,2-trifluoro-1-(9-
anthryl)ethanol (TFAE; 2), and econazole (3). 
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3.3 EPERIMENTAL SECTION 
Chemicals and Materials. (R)- and (S)-2,2,2-trifluoro-1-(9-anthryl)-1-ethanol (TFAE), (R)- 
and (S)-N-(3,5-dinitrobenzoyl)phenylglycine (DNBPG), econazole nitrite, HPLC grade 
tetrahydrofuran (THF), sulfated-β-cyclodextrin were purchased from Aldrich (Milwaukee, WI). 
Poly(vinyl) chloride (PVC; high molecular weight, Selectophore) and dioctyl sebacate (DOS; 
Selectophore) were purchased from Fluka (Ronkonkoma, NY). Water used in all the experiments 
was purified with a Milli-Q Synthesis A10 System (Millipore, Bedford, MA). The library of 
cyclopropyl dipeptide isosteres was provided by the University of Pittsburgh Center for 
Chemical Methodologies and Library Development (UPCMLD). Costar polypropylene 96-well 
microplates (flat-bottom, 330-µL well-volume), BD Falcon UV-transparent 96-well microplates 
(370-µL well-volume) and thermal adhesive sealing films were purchased from Fisher Scientific 
Co. (Pittsburgh, PA). 
Equipment. A Deep Well Maximizer (or BioShaker) (model M·BR-022 UP, made by Taitec 
and distributed by Bionexus Inc., Oakland, CA) was used to speed up the target distribution 
kinetics and control the temperature for better reproducibility. UV spectra were acquired with a 
SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA) in UV-transparent 
microplates. CE experiments were performed using a BioFocus 3000 (BioRad, Hercules, CA). A 
coated capillary with zero EOF (MicroSolv, Eatontown, NJ) was used to separate econazole 
racemates. 
General Procedure for Screening. Figure 3.1 gives the sequence of operations for the 
screening procedure. The plasticized PVC films were prepared in polypropylene 96-well 
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microplates. In this design, the aqueous phase contains target initially. Alternatively, target and 
selector may be combined in the film phase initially. After the target distribution between the 
two phases reached equilibrium, the supernatant was transferred to a UV-transparent microplate 
and the UV absorbance data were collected by a microplate reader to determine the target 
concentration in the aqueous phase. The partition coefficient, Kp, and target-selector complex 
formation constant, Kf, were then calculated based on the target concentrations at equilibrium. 
Detailed Protocol for Validation. PVC (2.5 g) and 2.5 g DOS were dissolved in 200 mL 
THF. 0.125 mg/mL (R)- and (S)-DNBPG, respectively, and 1 mg/mL (R)- and (S)-TFAE, 
respectively, were also prepared in THF. Polypropylene 96-well microplates were used to 
prepare the film phase. The volume of TFAE solution dispensed to each well is shown in Table 
3.1. A multi-channel pipette was used to dispense the solution. Three such plates were prepared. 
In plate 1 and 2, 100 µL of the (R)- and (S)-DNBPG solution, respectively, was dispensed to 
each well. There was no DNBPG in plate 3. All three plates were placed in the hood for 6 hours 
for evaporation of the THF. Two hundred µL of the PVC/DOS solution was then dispensed to 
each well. The plates were again placed in the hood for 6 hours for evaporation of the THF. Plate 
4 was prepared similarly, except for the contents in the wells, as shown in Table 3.2. After the 
films formed at the bottom of each well, 200 µL of 10 mM HCl was added. To speed up the 
kinetics, the microplate was placed in a shaker (500 rpm). This process was also temperature-
controlled at 25 ˚C to achieve better reproducibility. A thermal adhesive sealing film was used to 
cover the plate to prevent water from evaporation. One hundred µL of the supernatant from each 
well was then transferred to UV-transparent plates. A plate reader was used for UV absorbance 
measurements. Note that plate 3 and columns 5 and 6 of plate 4 were used for background 
subtraction. 
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Table 3.1. Layout of TFAE dispensed in the 96-well microplate for the validation (plates 1-3). 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
B 
C 
D 
E 
F 
G 
H 
(R)-TFAE 
50 µL 
(R)-TFAE 
100 µL 
(R)-TFAE 
150 µL 
(S)-TFAE 
50 µL 
(S)-TFAE 
100 µL 
(S)-TFAE 
150 µL 
 
 
Table 3.2. Layout of plate 4 for the validation. 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
B 
C 
D 
E 
F 
G 
H 
(R)-
DNBPG 
100 µL 
 
PVC/DOS 
200 µL 
(S)-
DNBPG 
100 µL 
 
PVC/DOS 
200 µL 
PVC/DOS 
200 µL NOT USED 
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Detailed Protocol for Screening. In the application of the screening, candidate selectors 
dissolved in DMSO were dispensed to the wells shown as in Table 3.3. Each well contains 50 
nmol of the candidate selector. DMSO is evaporated under vacuum and 200 µL of the PVC/DOS 
solution is then dispensed to each well of the plate. After evaporation of the THF, racemic 
econazole solutions (200 µL of 120 µM) prepared in phosphate buffer (25 mM, pH 3.0), and the 
buffer only, are added to the plate (Table 3.4). Again, after the equilibration in the shaker, 100 
µL of the supernatant from each well is transferred to a UV-transparent plate and the UV 
absorbance is measured by the plate reader. Buffer-only wells are for background subtraction. 
Calculations.  The volume of each film was estimated as 
   L
L
V
d
VmLgV solution
film
solution
film μμ 5.2100
200/5 ×≈×=     (3.1) 
Here Vsolution is the volume of the PVC/DOS solution used in each well, and dfilm is the density of 
the film which is estimated as 1 g/mL. In this work, 200 µL of PVC/DOS solution was dispensed 
in each well, so the volume of each film was about 5 µL. 
The concentration of the selector and target in the film, respectively, can be calculated as 
film
S
SS
S V
M
ConcV
C
×
=       (3.2) 
film
T
TT
T V
M
ConcV
C
×
=       (3.3) 
Here VS, ConcS and MS are the dispensed volume of the selector solution, the selector 
concentration in the solution and the selector molecular weight, respectively; VT, ConcT and MT 
are the dispensed volume of the target solution, the target concentration in the solution and the 
target molecular weight, respectively. 
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 The partition coefficient of the target, Kp, can be calculated as 
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where C0 is the initial target concentration in the aqueous phase (or the target concentration after 
all target partitions to the aqueous phase, when it is initially dissolved in the film phase), C1 is 
the target concentration at equilibrium, A0 and (A1 − Ab1) are the UV absorbance corresponding to 
C0 and C1, respectively, Ab1 is the UV absorbance due to small aqueous solubility of DOS, and Φ 
is the phase ratio. 
  If the target forms a 1:1 complex with the selector in the film phase, the binding 
constant of the complex can be calculated as 
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where Cr is the selector concentration in the film, C2 is the target concentration at equilibrium 
(when the film phase contains the selector), (A2 − Ab2) is the UV absorbance corresponding to C2, 
Ab1 is the UV absorbance due to small aqueous solubility of DOS and the selector. It is assumed 
that the selector is much more abundant than the target in the film and the selector concentration 
will not be apparently affected by the complex formation with the target.  
Capillary Electrophoresis (CE) Separation of Econazole Racemate Run buffer: 25 mM 
phosphate, pH 2.18, 4% (w/v) sulfated-β-CD; capillary: 60 cm in length, 50 cm to detection 
window, 50 µM i.d., 365 µM o.d., zero EOF ; E = - 15 kV; T = 25 ºC. Migration times were 
reasonably reproducible, but during a single run sometimes drifted (as did the current).  
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Table 3.3. Layout of the selector candidates in the 96-well microplate for the screening 
application. 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
B I V IX 
C 
D II VI X 
E 
F III VII XI 
G 
H 
 
IV VIII XII 
 
 
Table 3.4. Layout of the target solutions in the 96-well microplate for the screening application. 
1 2 3 4 5 6 7 8 9 10 11 12 
A Buffer Buffer Buffer 
B Econazole Econazole Econazole 
C Buffer Buffer Buffer 
D Econazole Econazole Econazole 
E Buffer Buffer Buffer 
F Econazole Econazole Econazole 
G Buffer Buffer Buffer 
H 
Buffer Econazole 
Econazole Econazole Econazole 
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3.4 RESULTS AND DISCUSSION 
As a validation of the method prior to application, a known pair of chiral selector and target was 
considered. When attached to a stationary support, DNBPG has a selectivity (α) of 1.3 ~ 1.6 to 
TFAE.8, 33 TFAE was defined as the selector, and the DNBPG release from the PVC/DOS film to 
the aqueous buffer solution was observed, with or without the selector in the film. As shown in 
Figure 3.3, ~4 h is needed for the distribution of DNBPG to reach equilibrium. Apparently, when 
the film contained the selector, less target solute was released. Compared to (S)-TFAE, (R)-
TFAE as the selector kept more (R)-DNBPG in the film phase. In this work, all the distribution 
experiments in the validation process were performed for 5 h to ensure equilibration. 
Figure 3.4 shows the dependence of the concentration of target in the aqueous phase at 
equilibrium on the selector concentration in the PVC/DOS film. Both selectors hindered the 
release of target in a concentration-dependent manner. At all selector concentrations, compared 
with (R)-TFAE, the use of (S)-TFAE caused more (R)-DNBPG to remain in the film phase; when 
(S)-DNBPG was the target, the opposite held true. The higher the selector concentration, the 
greater was the difference. Since a relatively low selector concentration minimizes the effect of 
TFAE self-association in the film (if it occurs), we determined Kf, (the formation constant for the 
(+)- and (-)-targets with the selector) and the selectivity, α, at the selector concentration of 36 
mM, and Kp (partition ratio) with no selector present. Table 3.5 shows the results. 
The formation constants are extremely small, yet complex formation influences 
partitioning. In a case like this, where material supply is not limited, we were able to perform a 
number of repeat measurements, adding significance to the measured absorbance differences.  
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Figure 3.3. Kinetic UV absorbance of (R)-DNBPG in the aqueous phase during the distribution 
equilibration process. 
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(R)-TFAE as selector 
(S)-TFAE as selector 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Effect of TFAE concentration in the film phase on DNBPG equilibrium 
concentration in the aqueous phase. 
Eight repeats were performed, and the error bars show the standard errors of the mean (SEM). 
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Table 3.5. Values of Kp for DNBPG going from PVC/DOS (1:1 w/w) film phase to 10 mM HCl 
phase and its Kf with TFAE in the film. 
Kf (M-1) 
Kp
R-R or S-S R-S or S-R 
α 
39.2 ± 0.2 5.8 ± 0.6 10.5 ± 0.6 1.8 ± 0.2 
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The value of selectivity is significant, and similar to the value found in chromatography cited 
above. It is likely that in normal organic solvents, the formation constants would be larger.30, 34-36 
In order for the solute distribution process to reveal binding, the solute partition coefficient Kp 
(distribution without selector) must be in a certain range (which depends on phase ratio). For 
accurate calculation of Kf, the selector should not be soluble in water and should have no self-
association in film. The effect of partitioning of selector into the aqueous phase is to reduce the 
sensitivity of the measurement to binding. 
This method was used to screen a small library of potential chiral selectors for econazole. 
This small library contained 12 cyclopropyl dipeptide isosteres. Racemic econazole solutions 
(120 µM) were prepared in phosphate buffer (25 mM, pH 3.0) and equilibrated with PVC/DOS 
films (phase ratio, Φ = 40), without selector and with selectors I-XII (Figure 3.5). The 
equilibrium optical absorbances in the aqueous phase for candidate selectors I-XII were 
compared to the control using the z distribution (Table 3.6; refer to Appendix A for a detailed 
discussion of Z-test). Eight of the 12 compounds show significant binding to econazole at the 
99% confidence level. 
As the racemate was used, chiral capillary electrophoresis (CE) was needed to determine 
the selectivity of econazole distribution. Among the 8 compounds, only selector X showed 
measurable enantioselective binding (Table 3.7). As indicated by the Peak 1/Peak 2 area ratio in 
the chiral CE trace (Figure 3.6), selector X binds the two enantiomers of econazole differently. 
Assuming no selector X was back-extracted to the aqueous phase, the selectivity is calculated to 
be 1.2. Though the selectivity is too low to use this compound as a chiral selector, it is 
remarkable that in this small sample we identified a selector. 
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Figure 3.5. Chemical structures of the library of 12 potential selectors. 
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Table 3.6. Binding of econazole to the potential selectors. 
Selector UV abs. (218nm) Na zb Kf (M-1) 
NO 0.737 24   
I 0.724 2 1.36 -- 
II 0.685 2 5.43 48 ± 9 
III 0.68 2 5.96 53 ± 9 
IV 0.661 2 7.94 73 ± 10 
V 0.741 2 0.418 -- 
VI 0.724 2 1.36 -- 
VII 0.677 2 6.27 57 ± 9 
VIII 0.641 2 10.0 96 ± 11 
IX 0.696 2 4.29 38 ± 9 
X 0.502 2 24.6 298 ± 17 
XI 0.676 2 6.38 58 ± 9 
XII 0.714 2 2.40 -- 
aNumber of repeats bDifference in absorbances divided by the error of the difference in 
absorbances (Appendix A). 
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Table 3.7. Peak area ratios from CE of econazole. 
Econazole 
Area Ratio  
(Peak 1 / Peak 2) 
SEM n 
Before extraction 0.980 0.002 6 
No selector 0.973 0.003 6 After 
extraction Selector X 1.051 0.009 16 
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 Figure 3.6. Chiral capillary electrophoresis separation of econazole nitrate. 
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There is a great deal of flexibility in this system. The sensitivity of the technique can be 
adjusted. While applicability to small values of α was demonstrated, it is also possible to set up a 
system in which a particular combination of Kf and α is discovered. In this high throughput 
screening application, only 200 nmol (<100 µg) of each library member was used. Because of 
the small mass requirements, it opens up huge numbers of compounds as candidate selectors. 
The same procedures can be used to test one selector vs. many solutes (i.e., generality). A 
detailed comparison of this method to the other approaches is shown in Table 3.8. 
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Table 3.8. Comparison of screening methods for chiral stationary phases. 
Screening 
Principle 
Preparation Detection 
Selector 
amount 
Covalent 
attachment of 
each selector 
to the solid 
phase 
N column 
packing 
HPLC 
separation 
According to 
column size 
HPLC 
separation on 
synthesized 
CSP 
Covalent 
attachment of 
the target 
analyte to the 
solid phase
One column 
packing 
HPLC 
separation 
According to 
column size 
20, 37
Covalent 
attachment of 
each selector 
to the solid 
phase
LC/MS for 
isotopically 
labeled 
enantiomers 
Analyte 
adsorption 
equilibrium 
~ 50 mg 
22 
Covalent 
attachment of 
each selector 
to the solid 
phase
Analyte 
adsorption 
equilibrium 
23, 25, 26 
(3 hours) 
Circular 
Dichroism or 
HPLC 
~ 15 mg 
(0.030 mmol) 
Selector-
analyte 
complex 
formation 
Membrane 
preparation UV absorbance 
(Plate reader, 
10 min for 96 
readings ) 
Analyte 
distribution 
~ 0.1 mg (<12 hours, 
including 10 
hours’ waiting 
time) 
(200 nmol) 
(1-5 hours) 
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3.5 CONCLUSIONS 
A new screening method for chiral selectors based on target distribution between a film phase 
and an aqueous phase is described. This method was validated by a known pair of chiral selector 
and target – TFAE and DNBPG, and applied to a small library of cyclopropyl dipeptide isosteres 
to screen chiral selectors for econazole. Compared to current screening methods, this format does 
not require any covalent attachment of either the target or the potential chiral selector to the 
stationary phase, which saves time and labor.  Moreover, the amount of the selector required by 
this method is at the microgram scale, which is about two orders of magnitude less than the 
amount needed by current screening processes.22  
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4.0  HIGH-THROUGHPUT PHASE-DISTRIBUTION METHOD TO DETERMINE 
DRUG-CYCLODEXTRIN BINDING CONSTANTS 
4.1 ABSTRACT 
A high-throughput method has been developed to measure drug-cyclodextrin binding constants.  
It measures the distribution coefficient of a drug between a polymer film (polyvinyl chloride 
(PVC) with 67% (w/w) dioctyl sebacate (DOS)) and a cyclodextrin-containing buffer in a 96-
well format. Measurements of distribution coefficient at several cyclodextrin concentrations lead 
to binding constants. Binding constants for econazole with six CDs have been determined in one 
96-well microplate with four replications of each condition in 10 hours. The K1:1 values are 
1662±159 M-1, 1964±51 M-1, 19600±5100 M-1, 373±77 M-1, 13190±300 M-1, 3100±160 M-1, 
with (2-hydroxyethyl)-β-cyclodextrin, (2-hydroxypropyl)-β-cyclodextrin, 2,6-di-o-methyl-β-
cyclodextrin, heptakis(2,3,6-tri-o-methyl)-β-cyclodextrin, α-cyclodextrin, β-cyclodextrin, 
respectively. It is likely that 1:2 complexes are also formed in some cases. This method has also 
been applied to study the binding behavior as a function of the drug concentration and pH. 
Binding weakens at higher drug concentration which may be due to the self-association of the 
drug. An acidic environment decreases the binding constant of CD with the basic econazole. The 
formation of the 1:2 complex is completely suppressed in acid as well. This protocol is faster 
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than the phase-solubility method. Moreover, the material requirement is up to 4 orders of 
magnitude lower.  
4.2 INTRODUCTION 
Aqueous solubility is one of the fundamental determinants in developing new chemical entities 
as successful drugs.1 Multiple formulation techniques exist to increase the apparent solubility of 
lipophilic compounds without decreasing their optimized potency. These techniques include 
particle size reduction, pH adjustment, addition of solubilising excipients, solid dispersion, 
microemulsification, nanocrystallization, inclusion complex formation, etc.2 Cyclodextrins 
(CDs) are bucket-shaped oligosaccharides produced from starch, with a hydrophilic outer surface 
and a lipophilic inner cavity. They are able to form water-soluble inclusion complexes with 
many lipophilic compounds. They are commonly used in pharmaceutical formulations to 
enhance drug solubility, stability and bioavailability.3, 4 To date, there are more than 20 marketed 
drugs that contain CDs,5 and numerous publications are emerging every year studying the use of 
CDs for drug formulation and delivery. Although higher order complexes are not uncommon, the 
simplest and most frequent stoichiometry of drug-cyclodextrin (S-CD) complexes is 1:1 
S + CD
K1:1
S-CD  
The binding constant (K ) is defined as 1:1
]][[
]-[
1:1 CDS
CDSK =       (4.1) 
where [S], [CD], [S-CD] are the concentrations of the free drug, free CD, and drug-CD complex, 
respectively. For consecutive complexation 
 90 
S-CDi-1 + CD
K1:i
S-CDi     
The binding constant (K ) is defined as  1:i
]][-[
]-[
1
:1 CDCDS
CDS
K
i
i
i
−
=       (4.2) 
The binding forces within the drug-CD complexes may involve hydrophobic, van der Waals, 
hydrogen bonding, or dipole interactions.6 Depending on the cavity size and functional groups, 
CDs vary in their ability to form inclusion complexes with specific guest compounds.7 The 
stoichiometry and binding constant are important in any investigation to assess the value of a CD 
for the formulation of a specific drug.8  
  Grounded on the basic principles of medicinal chemistry, one of the most reliable 
methods to increase in vitro potency of drug candidates is to add lipophilic moieties at 
appropriate positions of the lead compound.1 Hence the recent development of combinatorial 
synthesis and high-throughput technologies has led to an increasing number of poorly soluble 
compounds from combinatorial libraries being investigated for their therapeutic activities.9 To 
develop a formulation technique that works within the combinatorial screening regimen, it would 
be beneficial to have a universal protocol that can measure the binding constant of drug-CD 
complexes in a high-throughput manner. Various techniques exist to measure drug-CD binding. 
They can be generally classified into two groups: separation based and non-separation based. 
The former separates the free and complexed drug and quantifies their concentrations. 
Chromatography,10 affinity capillary electrophoresis (ACE),11-14 dialysis,15, and electrospray 
mass spectroscopy (ESI-MS)16 methods are separation based techniques. The latter group of 
methods monitors the change in specific physicochemical properties of the drug or CD upon 
complexation. This category includes for example spectroscopy,17, 18 NMR, conductometry,19 
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potentiometry,20 phase-solubility,21 and hydrolysis kinetics.22, 23 Each type of measurement is 
limited to a certain set of compounds. The most common method to determine K1:1 for drug-CD 
binding is the Higuchi-Connors phase-solubility method.21 This method measures the effect of 
CD concentration on the apparent solubility of the drug; the intrinsic solubility (S0) and the slope 
of the solubility vs. CD-content diagram are then used to calculate K1:1. There are also a few 
reports using phase-distribution methods to determine binding constants for CD complexes.24, 25 
High-throughput technologies have been employed in protein binding measurement using 
homogeneous and cell-based assays.26, 27 However, unique assays are required for each target, 
which leads to long development time and high cost.26 As to the author’s knowledge, there is no 
genuine high-throughput approach that has been developed for the determination of drug-CD 
complexation. 
Recently, we have developed a high-throughput method that can determine the partition 
and distribution behavior of drug candidates between a polymer phase and an aqueous phase.28 
This method has also been applied to measure intermolecular association in the polymer phase to 
screen chiral selectors.29 Here the application of this high-throughput method for the 
determination of drug-CD binding constants in the aqueous phase is reported. The polymer phase 
is composed of poly(vinyl chloride) (PVC) and dioctyl sebacate (DOS) at the ratio of 1:2 (w/w). 
Econazole and miconazole (Figure 4.1), both anti-fungal agents, were used as the test drugs. 
Their abilities to form water-soluble complexes with various CDs were determined under various 
concentration and pH conditions. 
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 Figure 4.1. Econazole (1) and miconazole (2). 
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4.3 EXPERIMENTAL 
Materials (2-Hydroxyethyl)-β-cyclodextrin (HE-β-CD), (2-hydroxypropyl)-β-cyclodextrin 
(HP-β-CD), 2,6-di-o-methyl-β-cyclodextrin (DM-β-CD), heptakis(2,3,6-tri-o-methyl)-β-
cyclodextrin (TM-β-CD), α-cyclodextrin (α-CD), and β-cyclodextrin (β-CD) were purchased 
from Sigma-Aldrich-Fluka at the highest available purities. Econazole free base was purchased 
form Molecula Ltd. (Dorset, UK). Miconazole free base was purchased from MP Biomedicals 
(Solon, OH). HPLC grade tetrahydrofuran (THF) and acetonitrile (ACN) were purchased from 
Aldrich (Milwaukee, WI). PVC (high molecular weight, Selectophore) and dioctyl sebacate 
(DOS; Selectophore) were purchased from Fluka (Ronkonkoma, NY). Water used in all the 
experiments was purified with a Milli-Q Synthesis A10 system (Millipore, Bedford, MA). Costar 
polypropylene 96-well microplates (flat-bottom, 330-µL well volume) and thermal adhesive 
sealing films were purchased from Fisher Scientific Co. (Pittsburgh, PA). 
Equipment  An UltraSpense 2000 microplate dispenser (KD Scientific, Holliston, MA) was 
used to prepare polymer films in 96-well plates. A Deep Well Maximizer (or BioShaker) (Model 
M·BR-022 UP, made by Taitec and distributed by Bionexus, Inc., Oakland, CA) was used to 
speed up the drug distribution kinetics and control the temperature for better reproducibility. An 
X-LC (Jasco, Inc.) HPLC system was used to determine the econazole and miconazole 
concentration with a UPLC C18 column (1.0 × 50 mm, particle size: 1.7 µM, Waters, Milford, 
MA). The molecular weights of the cyclodextrins in this study were determined by ESI-MS 
(Agilent HP 1100 LC-MSD). 
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Buffer Preparation The phosphate buffer solutions (20 mM, pH 5.8, 7.4, 8.5) were made by 
mixing appropriate amounts of 20 mM sodium phosphate dibasic solution and 20 mM sodium 
phosphate monobasic solution. The phosphate buffer (20 mM, pH 1.8) was made by mixing 
appropriate amounts of 20 mM sodium phosphate monobasic solution and 20 mM phosphoric 
acid solution.  
High-Throughput Phase-Distribution Studies  Figure 4.2 gives the sequence of operations 
for the phase-distribution method that measures the binding constants of drug-CD complexes. 
The plasticized PVC films were prepared in polypropylene 96-well microplates.  The detailed 
process is described elsewhere,28 with the exception that in this study a microplate dispenser 
rather than a multichannel pipet was used for solution dispensing. This provided higher 
throughput and better precision. Briefly, an appropriate amount of the PVC, DOS and drugs were 
dissolved in THF. Aliquots of 250 µL of this solution were dispensed by the microplate 
dispenser to microplates. Evaporation of solvent allowed the formation of polymer films at the 
bottom of each well. The volume of each film has been calculated to be ~2.5 µL.28 CD-
containing aqueous buffers were then manually dispensed over the films with a multichannel 
pipet. The plates were covered by adhesive sealing films and incubated in a shaker (500 rpm, 25 
ºC). In order to determine the equilibration time, the concentration of drug extracted into the 
aqueous phase was measured as a function of time. Other than for this experiment, all data 
generated were at equilibrium. To determine the drug concentration, the supernatant from each 
well was transferred to another plate and injected to the HPLC system by an autosampler. The 
distribution coefficient, D, was then calculated as 
( ) Φ⋅−= Etot
E
CC
CD       (4.3)   
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96-well plate 
Evaporate THF
Add CD-containing buffer 
Equilibrate (const. T) 
Transfer supernatant to
another plate, measure  
drug conc. by HPLC 
Add PVC/DOS/drug in THF
 
 
Figure 4.2. General procedure for binding constant measurement. 
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Here Ctot is the drug aqueous concentration if all the target has been extracted to the aqueous 
phase, CE is the drug aqueous concentration at equilibrium, and Φ is the phase ratio (aqueous 
over polymer). 
HPLC Method to Determine Econazole/Miconazole Concentration To minimize the 
ionized form, pH 1.8 samples were diluted 9 times with 20 mM pH 8.5 phosphate buffer; pH 5.8 
samples were diluted 3 times with 20 mM pH 8.5 phosphate buffer. The mobile phase was 
H O/acetonitrile (65/35), flowing at 0.2 mL/min through a Waters UPLC C2 18 column. The back-
pressure was ~480 bars. To ensure reproducibility, the full-load injection mode was used 
(injection volume 5 µL; loop volume 1 µL). The peak area was used for the calibration and 
determination of sample concentration. The time per analysis was ~60 s. 
ESI-MS Method to Determine Cyclodextrin Molecular Weights The mobile phase was 
acetonitrile/H2O (35/65) with 0.1% formic acid. The samples were introduced into the ESI 
source at 5 µL/min. All experiments were performed in positive ion mode. Typically, a probe 
high voltage ~4000 V was applied between the spray needle and the end plate. The drying gas 
temperature was 350 °C with the flow rate at 10 L/min. The nebulizer pressure was 29 psig. The 
mass scanning range was 100-3000 with a resolution of 0.15.  
Theories to Determine the Stoichiometry n and Binding Constants K1:i (i = 1 to n) The 
distribution of the free drug between the aqueous phase and the film phase is determined by the 
partition ratio D0
filmS
SD
][
][
0 =          (4.4) 
where [S] and [S]film are the free drug concentration in the aqueous phase and film phase, 
respectively. When the CD is added to the aqueous phase, the drug distribution coefficient is: 
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film
n
i
i
S
CDSS
D
][
]-[][
1
∑
=
+
=        (4.5) 
where n is the stoichiometry, [S-CDi] (i = 1 to n) is the drug-CD complex concentration in the 
aqueous phase in various forms. Dividing Eq. 4.5 by Eq. 4.4  
∑
=
+=
n
i
i
S
CDS
D
D
10 ][
]-[
1       (4.6) 
 
From Eq. 4.2, one obtains 
       (4.7) ∏
=
=
i
j
j
i
i KCDSCDS
1
:1]][[]-[
Inserting Eq. 4.7 to Eq. 4.6 
∑ ∏
= = ⎟
⎟
⎠
⎞
⎜⎜⎝
⎛+=
n
i
i
j
j
i KCD
D
D
1 1
:1
0
][1        (4.8) 
Plotting D/D0 versus [CD], the stoichiometry and the binding constants can be obtained from 
polynomial fitting analyses. In practice, a degree 1 (linear) fitting should first be performed, 
assuming that only 1:1 complex forms 
][1 1:1
0
CDK
D
D +=       (4.9) 
A proper fitting should give a straight line with a y-intercept of 1, and the slope can report the 
value of K1:1. Otherwise a degree 2 (quadratic) fitting should be carried out, assuming that both 
1:1 and 1:2 complexes form: 
2
2:11:11:1
0
][][1 CDKKCDK
D
D ++=    (4.10) 
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 and KAgain, a correct fitting should give a y-intercept of 1, and the K1:1 1:2 values can be 
obtained from the corresponding coefficients of the polynomial. If the fit is still not satisfactory, 
fitting analyses with higher degrees should be continued. Note that all the coefficients of the 
polynomial should have positive values. In this study, the concentration of CD prepared in the 
aqueous buffer (CCD) is much higher than the drug concentration (Ctot), hence the drug-CD 
complexation does not significantly change the free CD concentration, and [CD] in Eq. 4.8, 4.9 
and 4.10 can be reasonably replaced by CCD.  
4.4 RESULTS AND DISCUSSION 
A kinetic study was first performed to determine the time needed for the phase distribution of 
econazole to reach equilibrium. The results are shown in Figure 4.3. Clearly, 8-9.5 h is enough 
for all the distribution experiments being equilibrated. Careful inspection of the curves shows 
that the equilibration time is shorter when the aqueous phase contains less CD or the specific CD 
has a weaker ability to extract econazole. All other distribution experiments were allowed to 
equilibrate for 10 h. 
   Instructed by Eq. 4.8, the effect of CD concentration on the distribution of econazole was 
then studied. Figure 4.4 gives the profile of econazole equilibrium concentration versus CD-
content in the aqueous phase for six CDs. Each measurement was repeated for four times and the 
corresponding error bar indicates the standard error of the mean (SEM). The SEM values were 
then used in error propagations to determine the errors of the calculated distribution coefficients 
and D/D0 values. Ctot is 88.8 µM in this experiment. Apparently, at higher CD concentration, 
more econazole is extracted to the aqueous phase. For these six CDs, the ability to 
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 Figure 4.3. HPLC peak area of econazole in the aqueous phase during the distribution 
equilibration process. 
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 Figure 4.4. Effect of CD concentration on econazole equilibrium concentration in the aqueous 
phase. 
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econazole is in the order of DM-β-CD > α-CD > β-CD > HE-β-CD ≈ HP-β-CD > TM-β-CD, 
which is in good agreement with the previous kinetic study (Figure 4.3) and reported phase-
solubility data of several CDs (α-CD > β-CD > HP-β-CD).30 Quadratic polynomial fitting 
analyses according to Eq. 4.10 give the K1:1 and K1:2 values, as shown in Table 4.1. The errors 
are their standard deviations. Some of the fitted curves are shown in Figure 4.5 and all the 
coefficients of determination (COD) are listed in Table 4.1. Since β-CD is insoluble at 
concentrations higher than 1.25% (v/w), no fitting analysis was performed for the calculation of 
its binding constant. Instead, the equation described in Table 4.1 was used to determine its K1:1 
value based on the assumption that only 1:1 complex had formed. The econazole-CD binding 
constants (K1:1) discovered by phase-solubility studies have been reported for α-CD, HP-β-CD, 
and β-CD, which are 2630±260, 1540±150, and 1420±130 M-1, respectively.30 These values are a 
little bit off from the data in Table 4.1. However, since the pH and choice of buffer species have 
a great effect on the determination of binding constant,30 the literature values measured in pure 
water should only used for qualitative purposes. Since the binding constant of econazole with β-
CD was calculated without using the fitting analysis, to determine this value more accurately, a 
repeat of experiment with more data points at lower CD concentrations may be necessary. The 
K1:2 values of five CDs are larger than 0, indicating the formation of 1:2 complexes. The relative 
standard deviation (RSD) of K1:1 for econazole/DM-β-CD interaction is so large that K1:1 is not 
significantly different from 0. Another fitting analysis was performed assuming K1:1 = 0, and the 
obtained K1:2 has a much smaller RSD. This indicates that only the 1:2 complex formed for 
econazole/DM-β-CD binding. Most studies on imidazole-CD complexation have assumed a 1:1 
ratio,1, 31 but higher order complexes have also been reported.32-36 For instance, the stoichiometry 
of econazole/β-CD has been published by several groups to be 1:1,30, 37  while one study has 
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Table 4.1. Binding constants of econazole with six CDs. 
D0 Cyclodextrin M.W. (g/mol) K1:1 (M-1) K  (M-1) COD 1:2
aHE-β-CD ~1480 1662±159 17±3 0.9977 
aHP-β-CD ~1580 1964±51 13±1 0.9998 
19600±5100 72±23 0.9963 
aDM-β-CD ~1330 1.94±0.12 
x 10
0c
6 c,d
0.9462c-5(3.30±0.12)x10
TM-β-CD 1429.54 373±77 46±10 0.9979 
α-CD 972.84 13190±300 1.9±0.4 0.9997 
bβ-CD 1134.98 3100±160 N/A N/A 
a Randomly substituted, and their average molecular weights are determined by ESI-MS. 
b The stoichiometry of econazole-β-CD is assumed to be 1:1, and its K1:1 is calculated as 
CDCD
DK ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −= 1
0
1:1  
c Quadratic fitting with the restriction K  = 0.  1:1
d -2 This entry should be compared to the product K K1:1 1:2, and it has units of M .  
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 Figure 4.5. Quadratic polynomial fitting of D/D  versus CD concentration. 0
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32discovered the formation of 2:3 complex.  Our ESI-MS studies have observed the formation of 
DM-β-CD dimers and trimers, as demonstrated in Figure 4.6. The signals for high-order 
econazole/DM-β-CD complexes were not discovered which may be due to the limited sensitivity 
of the instrument.
   The drug distribution behavior at various Ctot values was studied. The corresponding 
equilibrium concentrations versus CD-concentration profiles are shown in Figure 4.7. The CD 
used was HP-β-CD and the pH of the aqueous buffer was 8.5. D , K  and K0 1:1 1:2 values are listed 
in Table 4.2. At higher Ctot, the D  value is greater and the K  and K0 1:1 1:2 values tend to be smaller. 
This interesting trend may be due to a decreasing drug activity coefficient as concentration is 
increased. This effect can explain the previous observation that binding constants determined by 
phase-solubility studies are smaller than by this method, since in phase-solubility experiments, 
the saturated econazole concentration is much higher than the equilibrium drug concentration in 
this distribution study. 
 This method has also been applied in the situation where two mixed drugs are studied at 
the same time. Since the CD concentration is large with respect to the sum of the drug 
concentrations, a ‘multiplex’ approach is possible. Miconazole is an analogue of econazole. Both 
of them were dissolved in the same polymer film. The extraction profile is shown in Figure 4.8. 
The values of D , K0 1:1 and K1:2 are listed in Table 4.2. From the data, miconazole is more 
lipophilic than econazole, and binds more strongly to HP-β-CD. When mixed with miconazole, 
the distribution coefficient of econazole is greater, and the binding constants K1:1 and K1:2 are 
smaller, which may be attributable to the decreased drug activity coefficient caused by 
association with miconazole. 
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[CD-C3H7+Na]+
1000         500 1500 2000   2500     3000 m/z
 
 
Figure 4.6. ESI-MS spectrum of DM-β-CD (10% w/v) and econazole after distribution 
equilibration. (DM-β-CD with various degrees of substitution exist) 
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 Figure 4.7. Effect of HP-β-CD concentration on econazole equilibrium concentration in the 
aqueous phase at various drug concentrations. 
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Table 4.2. Binding constants of econazole and miconazole with HP-β-CD at various drug 
concentrations. 
Drug Ctot (µM) D0 K1:1 (M-1) K  (M-1) COD 1:2
-644.4 (8.74±0.72)x10 1792±100 12±1 0.9999 
-588.8 (1.02±0.02)x10 1709±38 9.4±0.4 0.99997 
Econazole 
-5177.6 (1.49±0.12)x10 1225±30 7.2±0.4 0.99996 
88.8a -5(1.37±0.06)x10 1498±8 6.8±0.1 1.0000 
Miconazole 80.0b -6(1.46±0.39)x10 4052±416 10±2 0.9995 
a mixed with miconazole 
b mixed with econazole 
 
Table 4.3. Binding constants of econazole with HP-β-CD at various pH conditions. 
pH D0 K1:1 (M-1) K  (M-1) COD 1:2
-21.8 (1.36±0.07)x10 108±6 0 0.9932 
-35.8 (1.86±0.14)x10 270±9 0 0.9965 
-57.4 (3.30±0.12)x10 1964±51 13±1 0.9998 
-58.5 (1.02±0.02)x10 1747±174 6.4±2.3 0.9977 
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 Figure 4.8. Effect of HP-β-CD concentration on econazole and miconazole (mixed) equilibrium 
concentration in the aqueous phase. 
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   The binding behavior of econazole to HP-β-CD has been studied at various pH values. 
The drug equilibrium concentrations versus aqueous CD-concentration profiles are shown in 
Figure 4.9. The values of D , K0 1:1 and K1:2 are listed in Table 4.3. The K1:1 values at pH 8.5 and 
7.4 are not significantly different, but decrease rapidly in an acidic environment. Econazole is a 
basic compound and has a pKa value of 6.69,28  hence it can be concluded that increased 
ionization decreases its binding constant with CDs, which is consistent with literature 
observations.37 Moreover, the formation of the 1:2 complex is suppressed when econazole is 
ionized, as indicated by the values of K  = 0 at pH 5.8 and 1.8. 1:2
 Compared to the phase-solubility method, which can require days, this new technique is 
faster. Moreover, the drug amounts used in solubility experiments are much greater than in this 
method. For instance, the highest econazole concentration in a phase-solubility study is ~30 
mM,30 but in the phase-distribution experiment, Ctot is less than 0.1 mM. In addition, the volume 
of the CD solution used in a solubility study is typically 10 mL, which is 40 times more than in 
this distribution experiment. These two factors have led to a 12000-fold decrease in material 
requirements. The complexation of much less concentrated drug with cyclodextrins may be one 
of the reasons that the equilibration time is greatly shortened in these phase-distribution studies. 
For other phase-distribution methods, which study the drug distribution between an organic 
solvent and an aqueous phase, the solvent-CD complexation may lead to misinterpretation. In 
addition, entrainment and emulsion can be severe problems for very hydrophobic compounds,38 
and the handling of small volumes of organic solvent may be difficult.28  
   In phase-solubility studies, the accurate and precise determination of the intrinsic 
solubility (S ) is highly important for the accuracy and precision of K0 1:1. Similarly for this 
approach, the variance of D  may lead to misinterpretation of n and K as well. Since the drug 1:i 0
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Figure 4.9. Effect of HP-β-CD concentration on econazole equilibrium concentration in the 
aqueous phase at various pH conditions. 
 
 111 
 concentration is usually low (~0.01-0.1 µM) when determining D0, some error is inevitable. 
Ways to decrease the measurement error of D  have been discussed elsewhere.280  Among them, 
increasing determination repeats is the easiest to implement, which is convenient when using 
microtiter plates. 
4.5 CONCLUSIONS 
A new method to measure the binding constants of drug-CD complexes in the aqueous phase 
using high-throughput technologies was developed. This method measures the distribution 
behavior of a drug between a polymer phase and an aqueous phase in 96-well microplates. With 
four repeats, distribution coefficients of econazole respect to six CD-containing buffers at four 
different concentrations can be determined simultaneously. Quadratic polynomial correlations 
have been established to give the binding constants of econazole to the six CDs respectively. 
Both 1:1 and 1:2 complexes are found and the calculated K1:1 values can be correlated to some 
literature data from phase-solubility studies. The binding constants of econazole to HP-β-CD 
have been studied at various drug concentrations and pH conditions. At higher econazole 
concentrations, the drug-CD binding tends to be weaker, which may due to the self-association 
of the drug. An acidic environment weakens the binding between econazole with HP-β-CD and 
suppresses the 1:2 complex formation. Compared to the phase-solubility method, our protocol is 
much faster. Moreover, the material requirement decreases four orders of magnitude. This 
method has great flexibility as well, for instance, ‘multiplex’ approaches are possible due to the 
much lower concentration of the drug relevant to the CD concentration.  
 112 
4.6  REFERENCE 
(1) Loftsson, T.; Hreinsdottir, D.; Masson, M. International Journal of Pharmaceutics 2005, 
302, 18-28. 
(2) Das, N. G.; Das, S. K. Drug Delivery Report 2006, Spring/Summer, 52-55. 
(3) Hedges, A. R. Chemical Reviews (Washington, D. C.) 1998, 98, 2035-2044. 
(4) Uekama, K.; Hirayama, F.; Irie, T. Chemical Reviews (Washington, D. C.) 1998, 98, 
2045-2076. 
(5) Loftsson, T.; Brewster, M. E.; Masson, M. American Journal of Drug Delivery 2004, 2, 
261-275. 
(6) Hirsch, W.; Fried, V.; Altman, L. Journal of Pharmaceutical Sciences 1985, 74, 1123-
1125. 
(7) Bodor, N.; Buchwald, P. Journal of Inclusion Phenomena and Macrocyclic Chemistry 
2003, 44, 9-14. 
(8) Rao, V. M.; Stella, V. J. Journal of Pharmaceutical Sciences 2003, 92, 927-932. 
(9) Lipinski, C. A. Journal of Pharmacological and Toxicological Methods 2001, 44, 235-
249. 
(10) Chen, J.; Ohnmacht, C. M.; Hage, D. S. Journal of Chromatography, A 2004, 1033, 115-
126. 
(11) Schou, C.; Heegaard, N. H. H. Electrophoresis 2006, 27, 44-59. 
(12) Schipper, B. R.; Ramstad, T. Journal of Pharmaceutical Sciences 2005, 94, 1528-1537. 
 113 
(13) Karakasyan, C.; Taverna, M.; Millot, M.-C. Journal of Chromatography, A 2004, 1032, 
159-164. 
(14) Rundlett, K. L.; Armstrong, D. W. Electrophoresis 2001, 22, 1419-1427. 
(15) Sideris, E. E.; Georgiou, C. A.; Koupparis, M. A.; Macheras, P. E. Analytica Chimica 
Acta 1994, 289, 87-95. 
(16) Beni, S.; Szakacs, Z.; Csernak, O.; Barcza, L.; Noszal, B. European Journal of 
Pharmaceutical Sciences 2007, 30, 167-174. 
(17) Archontaki, H. A.; Vertzoni, M. V.; Athanassiou-Malaki, M. H. Journal of 
Pharmaceutical and Biomedical Analysis 2002, 28, 761-769. 
(18) Koopmans, C.; Ritter, H. Journal of the American Chemical Society, ACS ASAP. 
(19) Sheehy, P. M.; Ramstad, T. Journal of Pharmaceutical and Biomedical Analysis 2005, 
39, 877-885. 
(20) Kahle, C.; Holzgrabe, U. Chirality 2004, 16, 509-515. 
(21) Higuchi, T.; Connors, K. A. Advan. Anal. Chem. Instr. 1965, 4, 117-212. 
(22) Loukas, Y. L. Pharmaceutical Sciences 1997, 3, 343-346. 
(23) Loukas, Y. L.; Vraka, V.; Gregoriadis, G. International Journal of Pharmaceutics 1996, 
144, 225-231. 
(24) Masson, M.; Sigurdardottir, B. V.; Matthiasson, K.; Loftsson, T. Chemical & 
Pharmaceutical Bulletin 2005, 53, 958-964. 
(25) Eli, W.; Chen, W.; Xue, Q. Journal of Inclusion Phenomena and Macrocyclic Chemistry 
2000, 38, 37-43. 
(26) Senisterra, G. A.; Markin, E.; Yamazaki, K.; Hui, R.; Vedadi, M.; Awrey, D. E. Journal 
of Biomolecular Screening 2006, 11, 940-948. 
 114 
(27) Hallikas, O.; Taipale, J. Nature Protocols 2006, 1, 215-222. 
(28) Chen, Z.; Weber, S. G. Analytical Chemistry 2007, 79, 1043-1049. 
(29) Chen, Z.; Yang, Y.; Werner, S.; Wipf, P.; Weber, S. G. Journal of the American 
Chemical Society 2006, 128, 2208-2209. 
(30) Mura, P.; Faucci, M. T.; Manderioli, A.; Bramanti, G. Journal of Inclusion Phenomena 
and Macrocyclic Chemistry 2001, 39, 131-138. 
(31) Guillaume, Y. C.; Peyrin, E. Analytical Chemistry 1999, 71, 2046-2052. 
(32) Pedersen, M.; Bjerregaard, S.; Jacobsen, J.; Rommelmayer Larsen, A.; Mehlsen 
Sorensen, A. International Journal of Pharmaceutics 1998, 165, 57-68. 
(33) Pedersen, M. European Journal of Pharmaceutics and Biopharmaceutics 1994, 40, 19-
23. 
(34) El-Barghouthi, M. I.; Masoud, N. A.; Al-Kafawein, J. K.; Abdoh, A. A. Russian Journal 
of Physical Chemistry 2006, 80, 1050-1055. 
(35) Peeters, J.; Neeskens, P.; Tollenaere, J. P.; Van Remoortere, P.; Brewster, M. E. Journal 
of Pharmaceutical Sciences 2002, 91, 1414-1422. 
(36) Miyake, K.; Irie, T.; Arima, H.; Hirayama, F.; Uekama, K.; Hirano, M.; Okamaoto, Y. 
International Journal of Pharmaceutics 1999, 179, 237-245. 
(37) Pedersen, M.; Edelsten, M.; Nielsen, V. F.; Scarpellini, A.; Skytte, S.; Slot, C. 
International Journal of Pharmaceutics 1993, 90, 247-254. 
(38) Poole, S. K.; Poole, C. F. Journal of Chromatography, B: Analytical Technologies in the 
Biomedical and Life Sciences 2003, 797, 3-19. 
 
 115 
APPENDIX A 
1Z-TEST
The Z-test is a statistical test used in inference which determines if the difference between a 
sample mean and the population mean is large enough to be statistically significant.  
In order for the Z-test to be reliable, certain conditions must be met. The most important 
is that since the Z-test uses the population mean and population standard deviation, these must be 
known. The sample must be a simple random sample of the population. If the sample came from 
a different sampling method, a different formula must be used. It must also be known that the 
population varies normally (i.e., the sampling distribution of the probabilities of possible values 
fits a standard normal curve). If it is not known that the population varies normally, it suffices to 
have a sufficiently large sample, generally agreed to be ≥ 30 or 40. 
The test requires the following to be known: σ (the standard deviation of the population), 
μ (the mean of the population), x (the mean of the sample), and n (the size of the sample). 
First, calculate the standard error of the mean (SEM): SEM = n/σ ; then calculate the z 
score for the Z-test: z = (x − μ) / SEM; finally, the z score is compared to a Z table, a table which 
contains the percent of area under the normal curve between the mean and the z score. Using this 
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table will indicate whether the calculated z score is within the realm of chance or if the z score is 
so different from the mean that the sample mean is unlikely to have happened by chance. 
For the Z-test in Table 3.6, μ = 0.737. The value of σ has been experimentally determined 
to be 0.0135. For each sample, n = 2. According to the z table, z scores should be larger than 
2.33 to ensure that the sample mean is different from the population mean at the 99% confidence 
level.  
 
Reference 
(1) Caulcutt, R.; Boddy, R. Statistics for Analytical Chemists; Chapman & Hall: London, 
1983. 
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APPENDIX B 
ULTRASPENSE 2000 MICROPLATE DISPENSER USER’S GUIDE 
B.1 GENERAL OPERATION 
1. Turn the power ‘on’, the switch is located on the back, right-hand side of the instrument. 
2. Check the cleanness of the manifold; make sure channels are clean and free of debris. 
3. Attach the manifold to the instrument by pushing the tube to the end while tightening the 
screw.  
4. Insert the manifold into the holder, tighten the screw and adjust height. 
5. Verify that the waste container is aligned with the waste dispenser. 
6. Using the arrows to navigate through the main menu. 
7. When ‘Prime’ is on the screen, press enter to access the Prime menu. Hit ‘Yes’ to rinse 
the instrument with solvent. You may want to do this multiple times. 
8. Press ‘Esc’ to return to the main menu and navigate to ‘Run’, if you have already 
programmed your own dispensing process (otherwise go to B.2. first for programming). 
Select ‘enter’ to access the Run menu and choose your OWN program. Choose the 
number of plates (1 or 2) you want to dispense solution (usually 1). Then hit ‘enter’ to 
dispense the liquid. 
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9. Press ‘Esc’ to return to main menu. To save the liquid that is remaining in the tubing and 
to return it to the solvent container, access the ‘Back’ menu from the main menu. Select 
‘Yes’ to return the liquid. 
10. ‘Prime’ the instrument again (several times if needed) with solvent to rinse the 
instrument, followed by priming with ACN (as needed), and finally, prime the instrument 
with water several times. 
11. When finished, carefully remove the manifold; make sure it is clean; wrap with 
laboratory tissues and store in a safe place.  
12. Wrap the tubes with laboratory tissues and switch the power to ‘off’. 
13. Empty the waste container. You may need to do that between ‘prime’s. 
14. Turn off the instrument. 
B.2 PROGRAMMING 
‘Program’ the dispensing process: You can create a new one by selecting a program that is 
empty. The instrument can save up to 16 programs. 
1. Name your program (2 letters) 
2. Choose a starting position. 
3. Choose an ending position. 
4. Select columns you want liquid dispensed into. Columns 1-12 will display a 1 or 0. A 1 
means liquid will be dispensed into that column, a 0 means that it will not. 
5. Choose the sample volume, units are microliters. 
6. Choose pump speed (1-3). If unsure, ‘2’ is probably sufficient. 
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7. Choose prime volume. If unsure, choose 50 µL. 
8. When through programming, press ‘Esc’ to get back to main menu. 
B.3 SETUP 
‘Setup’ some basic parameters of the dispenser: For instance, the position of the manifold (if you 
change one), the pumping speed (1, 2, 3: 100-3800. Having been optimized so it is not suggested 
to change them.), minimal volume (DO NOT change it unless you have read the detailed manual, 
since it is related to the actual volume it dispenses.), the prime volume, the prime speed, etc. 
Please be advised to read the manual first before you ‘setup’ the instrument. 
B.4 TROUBLESHOOTING 
When the precision of the solvent dispensing is not satisfactory, it is necessary to check the 
performance of the dispenser. Several factors may affect the dispensing precision. 
1. Bubbles in the tubing. 
Solution: ‘Prime’. 
2. Polymer debris in the glass tips of the manifold. 
Solution: Remove the debris using a capillary with an outer diameter of ~360 µm. Gas 
dusters may also help. 
3. Solvent droplets remaining at the end of the glass tips (the most frequently occurred 
problem).  
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Solution: Keep the outside of the tips clean, especially when finishing an experiment. If 
necessary, ultrasonication may help. There is an alternative manifold that is equipped with 
stainless steel tips. It has been tested that the droplet problem was less severe when that 
manifold was used. However, other problems may occur and the precision was not improved. 
KD Scientific has been working on glass tips with ceramic coatings to solve the problem.  
To check the precision of the solvent dispensing, generally two approaches can be performed. 
Since the viscosity of a solution may have a great effect on the precision of the dispensing, the 
2nd approach is necessary for the preparation of PVC/DOS films. 
1. Dissolve a reference compound in water and dispense the solution into a 96-well UV-
transparent microplate. Check the UV absorbance of each well by a microplate reader. 
2. Dispense the PVC/DOS/THF solution into a 96-well polypropylene microplate. After the 
THF is dry, the weight of film in each well is measured to evaluate the precision. 
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APPENDIX C 
SOME TIPS IN THE EXPERIMENTAL SECTION TO IMPROVE REPRODUCIBILITY 
C.1 POLYMER FILM PREPARATION 
PVC is hard to dissolve in THF when the PVC/plasticizer ratio is larger than 1:1. To prevent 
from PVC agglomeration, it is necessary to intensively shake the flask immediately after a 
certain amount of THF is dispensed into the flask. It may take more than one day to dissolve if 
PVC agglomerates.  
 Ligand and/or solute can be prepared in the polymer/plasticizer/THF solution or in pure 
THF respectively. When prepared in the PVC/plasticizer/THF solution, only one dispensing is 
needed to make the polymer films hence the precision of the ligand (and/or solute) concentration 
in the films may be better. However, flexibility may be a problem if ligand (and/or solute) 
concentration-dependent experiments are performed. When ligand and solute are prepared in 
pure THF respectively, it is essential to dispense them first prior to dispensing the 
polymer/plasticizer solution. The plates are placed in the hood to allow the THF to evaporate. 
The polymer/plasticizer solution should then be dispensed but before the wells are completely 
dry. Gentle shaking may be necessary to allow the compounds in the wells to dissolve again. It is 
important to ensure that there is no compound remaining on the walls of the wells that is not 
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dissolved. Some covering is necessary when the plate is again placed in the hood for THF 
evaporation. Laboratory tissues are usually used. Covering will make the THF evaporation 
slower to ensure better reproducibility of the films. It has been observed that the solute 
distribution behavior may be affected by the film drying process.    
C.2 AQUEOUS SOLUTION DISPENSING 
For better flexibility, multi-channel pipettes are usually used to dispense aqueous solutions. Two 
pipettes can be basically used to deliver 50-250 µL aqueous solution into each well: a 100 µL x 
12 pipette and a 1 mL x 12 pipette. Note that it is not necessary to use all the channels. The 
former pipette is ideal when less than 100 µL solution is dispensed into each well. The latter one 
is more convenient when more than 200 µL solution in each well is dispensed, especially with 
the ‘multi-dispensing’ mode. However, the precision may be poorer in this mode. The pipettes 
need to be calibrated regularly. It has been found that the delivery volume may become less for 
the channels at the two sides after a certain period of time.   
 In the film preparation process and when the THF evaporates, the polymer film will form 
not only at the bottom but also on the wall of each well. Hence it is desired that the dispensed 
volume of the aqueous solution is at least 50 µL more than the maximum volume of the THF 
solution in a well to ensure that the whole film will be covered by the aqueous solution.  
 Cyclodextrin solutions are extremely adhesive in the pipette tips. The 100 µL x 12 pipette 
is suggested in this case. 
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